{"text": "Guidelines recommending systematic search for viral replication should be reinforced in HBV patients .HBV patients less frequently underwent liver biopsy and were less often considered for antiviral therapy compared with HCV patients .", "label": "", "metadata": {}, "score": "30.212423"}
{"text": "When taking only HBV patients with detectable viral replication into consideration , results remained unchanged .During the multivariate analysis , ALT was a major factor for performing liver biopsy or considering antiviral therapy in both groups .", "label": "", "metadata": {}, "score": "32.035606"}
{"text": "The observed interlaboratory variation might yield a significant difference in organ allocation in patients with high MELD scores .The characteristics and response rate to pegylated interferon and ribavirin ( PEG - INF + RBV ) of patients with chronic hepatitis C infected with genotype 5 are poorly documented .", "label": "", "metadata": {}, "score": "32.877007"}
{"text": "Carlsson T , Reichard O , Norkrans G , et al .Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon - alpha 2a and ribavirin according to virological response .", "label": "", "metadata": {}, "score": "34.059753"}
{"text": "Patient needing , according to the physician , the initiation of a combined therapy of pegylated interferon alfa plus Ribavirin .Negative HBsAg test and HIV - Elisa test .", "label": "", "metadata": {}, "score": "34.405922"}
{"text": "Nowadays the best treatment for chronic hepatitis C is the combination of Peg Interferon a plus ribavirin with 55 % of patients presented viral clearance after 6 or 12 months of therapy .", "label": "", "metadata": {}, "score": "34.76774"}
{"text": "Together , we conclude that serum apoB-100 concentrations could predict virological response to Peg - IFN plus RBV combination therapy in patients infected with HCV G1b , especially in those with the rs8099917 hetero / minor genotype .", "label": "", "metadata": {}, "score": "34.963493"}
{"text": "demonstrated that age and liver fibrosis predicted the response rate to PEG - INF and ribavirin combination therapy [ 6 ] .Few studies have investigated the impact of viral subtype on SVR genotype 1 patients .", "label": "", "metadata": {}, "score": "35.595016"}
{"text": "Recent guidelines on management of HBV patients should be reinforced .The characteristics and response rate to pegylated interferon and ribavirin ( PEG - INF + RBV ) of patients with chronic hepatitis C infected with genotype 5 are poorly documented .", "label": "", "metadata": {}, "score": "36.035194"}
{"text": "An open pilot study exploring the efficacy of fluvastatin , pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads .", "label": "", "metadata": {}, "score": "36.48367"}
{"text": "In another study ( 55 ) , 133 patients infected with HCV and HIV were randomly assigned to receive either peg - IFN - a-2a or standard IFN - a-2a with RBV .", "label": "", "metadata": {}, "score": "36.819016"}
{"text": "The purpose of this study was to elucidate the long - term outcome after interferon ( IFN ) therapy in chronic hepatitis C elderly patients ... .", "label": "", "metadata": {}, "score": "36.895844"}
{"text": "Data reported were : demographic figures , the nature of the underlying liver disease , presentation characteristics of the tumour , laboratory findings and choice of therapy .", "label": "", "metadata": {}, "score": "36.978542"}
{"text": "A subset of HCV-1 infected patients selected from within the study database were selected to match the HCV-5 sample for known prognostic factors .The primary comparative analysis showed that response to treatment with PEG - INF + RBV of HCV-5 is similar to HCV-1 and lower compared to HCV-2/3 .", "label": "", "metadata": {}, "score": "37.01501"}
{"text": "A subset of HCV-1 infected patients selected from within the study database were selected to match the HCV-5 sample for known prognostic factors .The primary comparative analysis showed that response to treatment with PEG - INF + RBV of HCV-5 is similar to HCV-1 and lower compared to HCV-2/3 .", "label": "", "metadata": {}, "score": "37.01501"}
{"text": "Carlsson T , Weiland O , Reichard O. Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin .", "label": "", "metadata": {}, "score": "37.035072"}
{"text": "To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus ( HCV ) for predicting sustained virological response ( SVR ) to pegylated interferon ( Peg - IFN)/ribavirin , when they were combined with virological response ... .", "label": "", "metadata": {}, "score": "37.086224"}
{"text": "During the initial antiviral treatment , significant re- ductions in serum ALT levels , viral load and hepatic inflammation were noted ( Po0.05 vs. baseline for all measures ) .", "label": "", "metadata": {}, "score": "37.10237"}
{"text": "Small studies showed that this long - term treatment strategy can maintain biochemical and virological responses and prevent liver histological progression in patients with an initial partial response to IFN therapy ( 118 , 119 ) .", "label": "", "metadata": {}, "score": "37.106197"}
{"text": "Lawitz EJ , Bala NS , Alamo Study Group , et al .Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous therapy [ abstract]. Gastro-", "label": "", "metadata": {}, "score": "37.20407"}
{"text": "142 patients were treated with the standard of care therapy - pegylated interferon in combination with ribavirin .80 percent of patients received pegylated interferon \u03b1 2a and 20 percent- \u03b1 2b .", "label": "", "metadata": {}, "score": "37.32656"}
{"text": "The aim of this study was to determine the suitable treatment period in patients who achieve virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C virus infection ... .", "label": "", "metadata": {}, "score": "37.68212"}
{"text": "Response to pegylated ( PEG ) interferon ( IFN ) and ribavirin is achieved only in 40 - 50 % of patients infected with hepatitis C virus ( HCV ) of genotype 1 in high viral loads , which needs to be improved ... .", "label": "", "metadata": {}, "score": "37.745296"}
{"text": "Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy .", "label": "", "metadata": {}, "score": "37.79205"}
{"text": "The secondary aim was to verify whether we had enough evidence to support the implementation of a short treatment course in subsets of patients with genotype 2 and 3 infection .", "label": "", "metadata": {}, "score": "38.02169"}
{"text": "We therefore con- ducted a randomized clinical trial to assess whether a 12-week regimen of a combination of PEG - IFN - a-2a and ribavirin was as efficacious as a 24-week regimen in patients with HCV genotype 2 or 3 .", "label": "", "metadata": {}, "score": "38.16468"}
{"text": "Of the 388 patients , 322 provided informed consent for liver biopsy .The dose of PEG - INF and ribavirin were modified as necessary according to the standard criteria and protocol [ 12 ] .", "label": "", "metadata": {}, "score": "38.257988"}
{"text": "View Article .Legrand - Abravanel F , Colson P , Leguillou - Guillemette L , et al .: Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy .", "label": "", "metadata": {}, "score": "38.332314"}
{"text": "A careful search for the minimal dose of ribavirin needed in combination treatment is necessary .Abstract .Background .The impact of viral subtype on the rate of sustained virological response ( SVR ) to antiviral therapy in patients chronically infected with hepatitis C genotype 1 subtype 1a and 1b has not been extensively investigated .", "label": "", "metadata": {}, "score": "38.759388"}
{"text": "Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b : amino acid substitutions in the core region and low - density lipoprotein cholesterol l .", "label": "", "metadata": {}, "score": "38.912983"}
{"text": "AIM : To evaluate the efficacy of early interferon alpha-2b in non - post - transfusion acute hepatitis C virus : a prospective study with historical comparison .", "label": "", "metadata": {}, "score": "38.92415"}
{"text": "Background / Aims : A large multicenter trial to compare the efficacy of peginterferon alfa-2a with interferon alfa-2a , in combination with ribavirin , in chronic hepatitis C patients .", "label": "", "metadata": {}, "score": "38.953407"}
{"text": "Background / Aims : A large multicenter trial to compare the efficacy of peginterferon alfa-2a with interferon alfa-2a , in combination with ribavirin , in chronic hepatitis C patients .", "label": "", "metadata": {}, "score": "38.953407"}
{"text": "Comparison of virological and biochemical relapse in patients with chronic hepatitis B , based on continuation or discontinuation of lamivudine monotherapy ... .Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads .", "label": "", "metadata": {}, "score": "39.753716"}
{"text": "Eur J Gastroenterol Hepatol 2006 ; 18 : 313 - 20 .de Vera ME , Smallwood GA , Rosado K , et al . Interferon- alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation .", "label": "", "metadata": {}, "score": "39.856483"}
{"text": "High - dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load .", "label": "", "metadata": {}, "score": "39.901245"}
{"text": "Upon initiation of interferon therapy , there is a rapid decline in viral load , reflecting the efficiency of interferon - dependent inhibi- tion of the production of the virus , its release , or both [ 4].", "label": "", "metadata": {}, "score": "39.970825"}
{"text": "Patients with mild hepatitis C should not be excluded \" a priori \" from the possibility of being treated , as treatment with pegylated interferon and ribavirin is safe and effective in this group .", "label": "", "metadata": {}, "score": "40.07135"}
{"text": "A meta - analysis of 48 studies examined the safety and efficacy of both standard IFN and peg - IFN in liver transplant recipi- ents ( 69 ) .", "label": "", "metadata": {}, "score": "40.142334"}
{"text": "In clinical studies , the presence of anti - PEG was strongly associated with rapid clearance of PEG - asparaginase and PEG - uricase .PEGylation of therapeutic agents will continue to be of significant value in medicine to reduce immunogenicity , antigenicity and toxicity as well as markedly reducing renal clearance , while maintaining drug efficacy .", "label": "", "metadata": {}, "score": "40.16961"}
{"text": "belg . , 2010 , 73 , 223 - 228 ) .Background The combination therapy of pegylated - interferon - a2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. Background The combination therapy of pegylated - interferon - a2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40 - 50 % of na\u0131\u00a8ve patients with genotype 1 and in around 80 % of na\u0131\u00a8ve patients with genotype 2 or 3 .", "label": "", "metadata": {}, "score": "40.23414"}
{"text": "belg . , 2010 , 73 , 223 - 228 ) .Background The combination therapy of pegylated - interferon - a2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. Background The combination therapy of pegylated - interferon - a2a plus ribavirin is considered as the standard of care for patients with chronic hepatitis C. A sustained viral response is obtained in 40 - 50 % of na\u0131\u00a8ve patients with genotype 1 and in around 80 % of na\u0131\u00a8ve patients with genotype 2 or 3 .", "label": "", "metadata": {}, "score": "40.23414"}
{"text": "Am J Transplant 2006 ; 6 : 1586 - 99 .Lavezzo B , Franchello A , Smedile A , et al .Treatment of recurrent hepatitis C in liver transplants : efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin .", "label": "", "metadata": {}, "score": "40.287582"}
{"text": "However , this was an observational study with some potential confunding factors : more than 23 % of the patients were concomitantly infected with HIV or HBV ; and nearly 35 % were interferon experienced patients .", "label": "", "metadata": {}, "score": "40.451923"}
{"text": "Hayashida et al .( 124 ) devel- oped a pretreatment predictive algorithm based on liver messenger RNA expression profiles rather than viral factors .In this validation study , the algorithm accurately predicted sustained / transient response and non - response rates of 97 and 86 % ( Po0.00001 ) , respectively , with IFN ( Po0.0001 ) and 87 % ( Po0.05 ) , respectively , with combination antiviral therapy .", "label": "", "metadata": {}, "score": "40.47606"}
{"text": "Factors predictive of response to interferon - alpha therapy in hepatitis C virus infection .Hepatology 1994 ; 19 : 1088 - 94 .Hadziyannis SJ , Sette H Jr , Morgan TR , et al . Peginterferon-", "label": "", "metadata": {}, "score": "40.800606"}
{"text": "Efficacy , tolerability and predictive factors for early and sustained virologic response in patients treated with weight - based dosing regimen of PegIFN alpha-2b ribavirin in real - life healthcare setting .", "label": "", "metadata": {}, "score": "40.870716"}
{"text": "Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir , peginterferon and ribavirin treatment .Norio Akuta Department of Hepatology , Toranomon Hospital , Tokyo , Japan Intervirology 55:417 - 25 .", "label": "", "metadata": {}, "score": "40.901875"}
{"text": "Although an early virological response is observed more frequently in the induction treatment , end of treatment response and sustained responses did not differ .The standard treatment for patients with chronic hepatitis C is a 6 - 12-month combination therapy with interferon alpha and ribavirin .", "label": "", "metadata": {}, "score": "41.188637"}
{"text": "Patients and methods : This study was a multicenter , prospective , randomized clinical trial .Results : Sustained virologic response rates were similar in na\u00efve patients and relapsers , both for non - pegylated and pegylated interferon ( respectively 27 and 26 % and 54 and 43 % ) .", "label": "", "metadata": {}, "score": "41.317398"}
{"text": "Patients and methods : This study was a multicenter , prospective , randomized clinical trial .Results : Sustained virologic response rates were similar in na\u00efve patients and relapsers , both for non - pegylated and pegylated interferon ( respectively 27 and 26 % and 54 and 43 % ) .", "label": "", "metadata": {}, "score": "41.317398"}
{"text": "A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branched - chain amino acid ( BCAA ) granules for oral use ( TK-98 ) on disease progression ... .", "label": "", "metadata": {}, "score": "41.337696"}
{"text": "However , our results are in agreement with those reported by von Wagner et al.[17 ] from a randomized study comparing 16 weeks with 24 weeks of combination therapy with PEG - IFN - a-2a plus a weight - dependent ribavirin dosage in patients infected with HCV genotype 2 or 3 .", "label": "", "metadata": {}, "score": "41.497467"}
{"text": "Yasuji Arase Department of Hepatology , Toranomon Hospital , Tokyo Intern Med 46:1155 - 60 .The aim of this study was to evaluate whether or not combination therapy of pegylated interferon ( IFN ) and ribavirin for chronic hepatitis ( CH ) C patients enhances the serum level of KL-6 , a sensitive marker for interstitial pneumonia ... .", "label": "", "metadata": {}, "score": "41.58413"}
{"text": "We hypothesize that , in particular , an high rate of anemia could have been responsible for ribavirin or peginterferon dose modification in the AIFA study ( data not reported ) .", "label": "", "metadata": {}, "score": "41.595478"}
{"text": "Nutritional status is well recognized as a prognostic factor to these patients .Aim : The aim of this study was evaluate the nutritional status of hepatitis C patients submitted to antiviral therapy with Peg Interferon \u00e1 and ribavirin .", "label": "", "metadata": {}, "score": "41.605408"}
{"text": "Roth D , Cirocco R , Zucker K , et al .De novo membrano- proliferative glomerulonephritis in hepatitis C virus - in- fected renal allograft recipients .", "label": "", "metadata": {}, "score": "41.76042"}
{"text": "During the treatment phase , all patients received PEG - IFN - a-2a 180 \u03bcg / week + ribavirin 800 - 1200 mg / day .", "label": "", "metadata": {}, "score": "41.929653"}
{"text": "Large - scale studies of each mutant type should be conducted in the future to confirm these findings ... .Selection of a virus strain resistant to entecavir in a nucleoside - naive patient with hepatitis B of genotype H .", "label": "", "metadata": {}, "score": "41.949135"}
{"text": "This question will likely be answered as more co - infected patients are treated successfully with anti - HCVagents .Liver transplantation Graft re - infection in liver transplantation resulting from chronic HCV infection is common , as the virus is seeded from the bloodstream to the new graft ( 61 ) .", "label": "", "metadata": {}, "score": "41.972908"}
{"text": "A short waiting time from presentation to treatment appears as the most relevant predictive factor for sustained response .The standard treatment for patients with chronic hepatitis C is a 6 - 12-month combination therapy with interferon alpha and ribavirin .", "label": "", "metadata": {}, "score": "41.97899"}
{"text": "There are many factors influencing therapy result ; sometimes it is hard to understand which of them is the most essential .During recent years there are publications of interleukin 28B gene polymorphism as a strong predictor of SVR in patients treated with pegylated interferon and ribavirin .", "label": "", "metadata": {}, "score": "42.00357"}
{"text": "PubMed View Article .Hadziyannis SJ , Sette H Jr , Morgan TR , et al .: PEGASYS International Study Group .Peginterferon - alpha2a and ribavirin combination therapy in chronic hepatitis C : a randomized study of treatment duration and ribavirin dose .", "label": "", "metadata": {}, "score": "42.05993"}
{"text": "Soriano V , Nunez M , Camino N , et al .Hepatitis C virus- RNA clearance in HIV - coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin .", "label": "", "metadata": {}, "score": "42.063385"}
{"text": "There were 159 chronic viral hepatitis C patients included in the study .In order to detect IL-28B gene polymorphism , we used molecular biology techniques and methods : classical DNA separation , amplification by PCR , and standard sequencing .", "label": "", "metadata": {}, "score": "42.09246"}
{"text": "Treatment with pegylated interferon ( peg - IFN ) plus ribavirin improves hepatic enzyme levels and eradicates the virus in approximately 50 % of patients ; however , a significant number of patients do not respond to therapy or relapse following treatment discontinuation .", "label": "", "metadata": {}, "score": "42.12068"}
{"text": "In the ACCELERATE study [ 16 ] , the rate of SVR in patients treated with PEG - IFN - a-2a and ribavirin for 16 weeks was lower than that in patients treated for 24 weeks ( 62 % vs 70 % ) .", "label": "", "metadata": {}, "score": "42.20301"}
{"text": "Results : After multivariate analysis , the drop in hemoglobin level was only significant influenced by pretreatment platelet level , treatment and haptoglobin phenotype .The ribavirin dose did not influence the drop in hemoglobin level or the early virological response .", "label": "", "metadata": {}, "score": "42.338432"}
{"text": "Giostra E , Kullak - Ublick GA , Keller W , et al .Ribavirin/ interferon - alphasequential hepatitis C after liver transplantation .Transpl Int 2004 ; 17 : 169 - 76 .", "label": "", "metadata": {}, "score": "42.419464"}
{"text": "Similarly , methods ( e.g. measuring viral load early in the treatment course ) may help to predict poor response and determine the need for treatment modifications .", "label": "", "metadata": {}, "score": "42.491245"}
{"text": "Pegylated interferon alpha-2a 180 mcg weekly plus adjusted dose ribavirin for 48 weeks .Drug : Pegylated interferon alpha-2a .Background : The introduction of Peg interferon and Ribavirin ( an oral nucleoside analogue ) for chronic Hepatitis C has led to the concept that chronic hepatitis C ( HCV ) is a curable disease .", "label": "", "metadata": {}, "score": "42.605335"}
{"text": "J Clin Virol 2004 ; 30 : 110 - 4 .Calanca LN , Fehr T , Jochum W , et al .Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone .", "label": "", "metadata": {}, "score": "42.728596"}
{"text": "This study identified predictors of efficacy of PEG - IFN - RBV therapy based on viral kinetics in Japanese patients infected with HCV genotype 1b ... .", "label": "", "metadata": {}, "score": "42.92376"}
{"text": "Weiner SM , Thiel J , Berg T , et al .Impact of in vivo complement activation and cryoglobulins on graft outcome of HCV - infected renal allograft recipients .", "label": "", "metadata": {}, "score": "42.93774"}
{"text": "It is possible that the SVR rate in non - RVR patients and non - responder patients could also be improved by prolonging therapy , but this must be specifically investigated in other studies along with the role of IL28B polymorphisms .", "label": "", "metadata": {}, "score": "43.06565"}
{"text": "Conclusion : Our data indicate that treatment of chronic hepatitis C with PEG - IFN alfa-2b plus weight - based ribavirin results in favourable treatment outcomes in a Belgian cohort of patients treated in community- based clinical practice .", "label": "", "metadata": {}, "score": "43.09013"}
{"text": "At present the superiority of one regimen over the other in terms of treatment efficacy remains unknown .The interleukin-28B ( IL28B ) polymorphism has been reported to influence viral kinetics and SVR in genotype 1 patients [ 22 ] .", "label": "", "metadata": {}, "score": "43.114853"}
{"text": "Yasuji Arase Department of Hepatology , Toranomon Hospital , Tokyo , Japan Intervirology 51:265 - 9 .The aim of this study was to elucidate the efficacy of interferon ( IFN ) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load ... .", "label": "", "metadata": {}, "score": "43.371605"}
{"text": "The aim of this study was to investigate whether YMDD mutants occur in nature ... .Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis .", "label": "", "metadata": {}, "score": "43.398758"}
{"text": "Response to treatment in patients with chronic hepatitis C , with reference to age and gender , has not been examined fully ... .Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C .", "label": "", "metadata": {}, "score": "43.455864"}
{"text": "The aim of this study was to clarify potential factors , including benefit of lamivudine therapy , which could influence clinical course of the serious disease in an area of intermediate HBV endemicity ... .", "label": "", "metadata": {}, "score": "43.455864"}
{"text": "As stated above , HCV progression is likely enhanced in co - infected patients and , therefore , may justify more aggressive and earlier therapy .", "label": "", "metadata": {}, "score": "43.699577"}
{"text": "Advances in imaging technology have enhanced the detection of small nodular lesions during the course of chronic liver disease ... .Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan .", "label": "", "metadata": {}, "score": "43.75052"}
{"text": "Norio Akuta Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan J Med Virol 78:83 - 90 .Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir , peginterferon , and ribavirin .", "label": "", "metadata": {}, "score": "43.760757"}
{"text": "Liver histology and viral HCV - RNA levels seem to be particularly important predictor of response in these patients .A recent study by Cheng et al . showed that na\u00efve genotype-1 patients with advanced fibrosis were less likely to achieve SVR than those without advanced fibrosis [ 5 ] .", "label": "", "metadata": {}, "score": "43.796745"}
{"text": "Examination of the fasting lipid profile has clinical importance in predicting the efficacy of peg - IFN - \u03b1-2b plus RBV combination therapy for patients with HCV G1b even after the discovery of the IL28 genotype as a potent predictive factor .", "label": "", "metadata": {}, "score": "44.046825"}
{"text": "In contrast , modelling HCV kinetics within the first few weeks of IFN therapy is used in the ambulatory care setting and is key to maximizing individual patient outcomes ( 125 ) .", "label": "", "metadata": {}, "score": "44.068016"}
{"text": "Finally , we would like to emphasise that this study was conducted in \" real- world- patients \" , thus providing a representative picture of HCV treatment .", "label": "", "metadata": {}, "score": "44.185562"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : We investigated the early virological response ( EVR ) to peginterferon ( Peg - IFN ) \u03b1-2a plus ribavirin ( RBV ) and Peg - IFN\u03b1-2b plus RBV therapy in 125 Japanese patients infected with hepatitis C virus ( HCV ) genotype 1b .", "label": "", "metadata": {}, "score": "44.317093"}
{"text": "Methods : MELD scores were calculated in 66 patients with liver cirrhosis using bilirubin , creatinine , and INR analyzed in six liver transplant centers .", "label": "", "metadata": {}, "score": "44.344803"}
{"text": "Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin .", "label": "", "metadata": {}, "score": "44.34577"}
{"text": "Interferon - alpha- induced acute renal allograft rejection .Transplantation 1995 ; 59 : 1068 - 70 .Morales JM , Campistol JM .Transplantation in the patient with hepatitis C. J Am Soc Nephrol 2000 ; 11 : 1343 - 53 .", "label": "", "metadata": {}, "score": "44.421185"}
{"text": "The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis ... .A matched case - controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan : amino acid substitutions in HCV core region as predictor of sustained virological response .", "label": "", "metadata": {}, "score": "44.495426"}
{"text": "All patients managed to complete the one year treatment period but all needed EPO and two were transfused .Patient 's global exposure to Ribavirin as evaluated by the area under the curve ( AUC ) seems more pertinent in terms of exposure - effect relationship than measuring Ribavirin level at any single time point .", "label": "", "metadata": {}, "score": "44.858856"}
{"text": "Lipoprotein profiles were examined using fasting sera from 108 patients infected with HCV G1b who had chronic hepatitis , as determined by liver biopsy .In addition , significant predictive factors independently associated with virological response to peg - IFN\u03b1-2b plus RBV were determined by logistic regression analysis .", "label": "", "metadata": {}, "score": "45.236046"}
{"text": "This study compared four groups of patients with increasingly severe liver disease , as determined by Ishak scores and platelet counts .SVR rates decreased from 23 to 9 % as Ishak scores increased and platelet counts decreased ( Po0.0001 for trend ) , confirming the effect of advanced liver disease in antiviral therapy ( 33 ) .", "label": "", "metadata": {}, "score": "45.283154"}
{"text": "Ouzan D , Khiri H , Penaranda G , Joly H , Halfon P. Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naive genotype 1 patients .", "label": "", "metadata": {}, "score": "45.35807"}
{"text": "Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy .Norio Akuta Department of Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 83:1016 - 22 .", "label": "", "metadata": {}, "score": "45.399803"}
{"text": "Identifying risk factors and measuring viral load early in the treatment can help to predict response to IFN therapy and determine the need to modify or discontinue treatment .", "label": "", "metadata": {}, "score": "45.443848"}
{"text": "Namba et al .( 22 ) suggested that genetic alterations within the cell lines underlie IFN resistance ; however , further research is needed to explain fully the mechanisms of antiviral resistance in HCV infection .", "label": "", "metadata": {}, "score": "45.50784"}
{"text": "Both groups received 1000 - 1200 mg of ribavirin from week 4 until the end of the treatment .The drop in hemoglobin level was defined as the dift'erence between the pretreatment hemoglobin level and the hemoglobin level at week 8 .", "label": "", "metadata": {}, "score": "45.52366"}
{"text": "Ahmad J , Dodson SF , Demetris AJ , Fung JJ , Shakil AO .Recurrent hepatitis C after liver transplantation : a nonran- domized trial of interferon alfa alone versus interferon alfa and ribavirin .", "label": "", "metadata": {}, "score": "45.537712"}
{"text": "Yasuji Arase Department of Hepatology , Toranomon Hospital , Tokyo Intern Med 47:1085 - 90 .The aim of this study was to elucidate the efficacy of short - term interferon ( IFN ) therapy for type C cirrhotic patients with genotype 2a and low virus load ... .", "label": "", "metadata": {}, "score": "45.54733"}
{"text": "Cornberg M , Hadem J , Herrmann E , et al .Treatment with daily consensus interferon ( CIFN ) plus ribavirin in non-responder patients with chronic hepatitis C : a randomized open - label pilot study .", "label": "", "metadata": {}, "score": "45.567245"}
{"text": "10 , pp .532 - 535 , 2011 .View at Google Scholar . A. J. Thompson , A. J. Muir , M. S. Sulkowski et al . , \" Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus , \" Gastroenterology , vol .", "label": "", "metadata": {}, "score": "45.58194"}
{"text": "Neumann AV , Zeuzem S , Brunda MJ , Hoffman JH : Rapid viral response to treatment with pegylated ( 40KD ) interferon alfa-2a ( Pegasys ) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C ( CHC ) .", "label": "", "metadata": {}, "score": "45.62285"}
{"text": "Dalgard O , Bjoro K , Hellum KB , Myrvang B , Ritland S , Skaug K , Raknerud N , Bell H : Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks : a pilot study .", "label": "", "metadata": {}, "score": "45.662266"}
{"text": "The aim of this study was to elucidate the long - term outcome after hepatitis B surface antigen ( HBsAg ) seroclearance in a large number of Japanese patients ... .", "label": "", "metadata": {}, "score": "45.96318"}
{"text": "In fact , in this subset of patients , short - term therapy may improve the clinical outcome of HCV with fewer adverse effects related to long - term therapy .", "label": "", "metadata": {}, "score": "45.96672"}
{"text": "Official Title : .Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted - dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 .", "label": "", "metadata": {}, "score": "45.976208"}
{"text": "Kamar N , Ribes D , Izopet J , Rostaing L. Treatment of hepatitis C virus infection ( HCV ) after renal transplanta- tion : implications for HCV - positive dialysis patients await- ing a kidney transplant .", "label": "", "metadata": {}, "score": "46.133472"}
{"text": "Such modeling may be useful in developing individual tailoring and optimization of ribavirin dosage .By univariate analysis , prior treatment response ( na\u00efve or relapse ) , high platelet count , low AST level , low viral load contributed significantly to RVR .", "label": "", "metadata": {}, "score": "46.216118"}
{"text": "Zeuzem S , Herrmann E , Lee J - H , Fricke J , Neumann AU , Modi M , Colucci G , Roth WK : Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a .", "label": "", "metadata": {}, "score": "46.51277"}
{"text": "Blatt LM , Mutchnick MG , Tong MJ , et al .Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States .", "label": "", "metadata": {}, "score": "46.520584"}
{"text": "Antibodies are found in 2.4 % of the population , with HCV - RNA prevalence of 1.7 % of general population [ 2 ] .The outcome of HCV infection varies from spontaneous viral clearance , symptom free - HCV carrier state to chronic hepatitis , cirrhosis , and hepatocellular carcinoma .", "label": "", "metadata": {}, "score": "46.58886"}
{"text": "Clin Nephrol 2005 ; 63 : 232 - 5 .Teta D , Luscher BL , Gonvers JJ , Francioli P , Phan O , Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients .", "label": "", "metadata": {}, "score": "46.705"}
{"text": "However , after the discovery of single nucleotide polymorphisms near the IL28B gene ( rs8099917 and rs12979860 ) as potent predictive factors affecting the response to peg - IFN plus RBV , lipid factors are thought to be confounding factors .", "label": "", "metadata": {}, "score": "46.73111"}
{"text": "Shiffman ML , Hofmann CM , Contos MJ , et al .A rando- mized , controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia .", "label": "", "metadata": {}, "score": "46.88562"}
{"text": "Detail Information .Publications 111 found , 100 shown here .Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b .", "label": "", "metadata": {}, "score": "46.906456"}
{"text": "( 127 ) noted that patients achieving SVR with standard IFN 3MU plus RBV had a 79 % decline in HCV RNA levels following the first IFN dose .", "label": "", "metadata": {}, "score": "46.929882"}
{"text": "Based on available data , patients with early HCV RNA clearance are more likely to experience SVR than patients exhibiting later declines in viral load .", "label": "", "metadata": {}, "score": "46.980858"}
{"text": "After 1 week of peg- IFN - a-2a 180mg / week in patients with HCV genotype non-1 , a 2-log10copies / mL decline in HCV RNA levels was associated with an 89 % positive predictive value for SVR .", "label": "", "metadata": {}, "score": "47.03816"}
{"text": "Hepatitis C virus- associated membranoproliferative glomerulonephritis in renal allografts .J Am Soc Nephrol 1996 ; 7 : 2469 - 75 .Cruzado JM , Carrera M , Torras J , Grinyo JM .", "label": "", "metadata": {}, "score": "47.06778"}
{"text": "Identifying the risk factorsforpoorresponsecanaidcliniciansinpredicting response and making treatment and retreatment deci- sions .This article describes viral and host - related risk factors for poor treatment response to initial IFN therapy , evaluates current pharmacological options for the difficult - to - treat HCV - infected population and dis- cusses methods to predict potential treatment failure .", "label": "", "metadata": {}, "score": "47.074455"}
{"text": "Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon - ribavirin combination therapy .", "label": "", "metadata": {}, "score": "47.087925"}
{"text": "Chalasani N , Manzarbeitia C , Ferenci P , et al .Peginterferon alfa-2a for hepatitis C after liver transplantation : two randomized , controlled trials .", "label": "", "metadata": {}, "score": "47.150185"}
{"text": "DNA at a prolonged time after seroclearance of hepatitis B surface antigen ( HBsAg ) ... .Inhibitory effect of branched - chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus .", "label": "", "metadata": {}, "score": "47.232704"}
{"text": "Dalgard O , Bjoro K , Ring Larsen H , Bjornsson E , Holberg - Petersen M , Skovlund E : Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response .", "label": "", "metadata": {}, "score": "47.25541"}
{"text": "McHutchison JG , Lawitz EJ , Shiffman ML , et al .: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection .", "label": "", "metadata": {}, "score": "47.31907"}
{"text": "Thompson AJ , Muir AJ , Sulkowski MS , et al .: Interleukin-28B polymorphism improves viral kinetics and is the strongestpretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus .", "label": "", "metadata": {}, "score": "47.35339"}
{"text": "In a study of peg - IFN - a-2a and RBV , Fried et al .( 9 ) noted that an HCV genotype other than 1 was an independent and significant predictor of SVR ( odds ratio , 3.25 ; 95 % confidence interval , 2.09 - 5.12 ; Po0.001 ) .", "label": "", "metadata": {}, "score": "47.471825"}
{"text": "Two hundred and ten patients received PEG - IFN - alpha-2a ( 180 ug / week ) and ribavirin ( 800 - 1200 mg / day ) for 4 weeks .", "label": "", "metadata": {}, "score": "47.548374"}
{"text": "The natural history of the disease should also be a major factor in deciding on a course of therapy , as patients with mild or no fibrosis may not require such aggressive therapy .", "label": "", "metadata": {}, "score": "47.58541"}
{"text": "A randomized open label , multicenter studyevaluating the efficacy of peginterferon alfa 2a , in combination with ribavirin , in na\u00efve and relapsed chronic hepatitis C patient .", "label": "", "metadata": {}, "score": "47.627975"}
{"text": "Pretreatment predic- tion of interferon - alfa efficacy in chronic hepatitis C patients .Clin Gastroenterol Hepatol 2005 ; 3 : 1253 - 9 .Herrmann E , Zeuzem S. The kinetics of hepatitis C virus .", "label": "", "metadata": {}, "score": "47.66164"}
{"text": "Furthermore , advanced fibrosis is a predictor of non response to antiviral treatment in patients with genotype 1 virus [ 5 - 7 ] .Very few studies have examined whether the subtype of genotype 1(1a or 1b ) affects the rate of SVR [ 7 - 10 ] .", "label": "", "metadata": {}, "score": "47.80976"}
{"text": "Methods : Two hundred and ten patients received PEG - IFN - alpha-2a ( 180 ug / week ) and ribavirin ( 800 - 1200 mg/ day ) for 4 weeks .", "label": "", "metadata": {}, "score": "47.86311"}
{"text": "Methods .For 48 weeks , 388 \" na\u00efve\"genotype 1 patients were treated weekly with PEG - IFN \u03b1-2a or PEG - INF \u03b1-2b combined with daily ribavirin ( 1000 - 1200 mg / day ) .", "label": "", "metadata": {}, "score": "47.97169"}
{"text": "PubMed View Article .Ascione A , De Luca M , Tartaglione MT , et al .: Peginterferon alfa-2a plus ribavirin is nore effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection .", "label": "", "metadata": {}, "score": "47.97567"}
{"text": "Perez - Olmeda M , Nunez M , Romero M , et al .Pegylated IFN - a2b plus ribavirin as therapy for chronic hepatitis C in HIV - infected patients .", "label": "", "metadata": {}, "score": "48.006886"}
{"text": "PubMed View Article .Fried MW , Shiffman ML , Reddy K , et al .: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection .", "label": "", "metadata": {}, "score": "48.014397"}
{"text": "Terrault NA , Pawlotsky JM , Mchutchison J , et al .Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy .", "label": "", "metadata": {}, "score": "48.053375"}
{"text": "Zein et al .found no difference in SVR rates between subtype 1a and 1b patients treated with standard interferon [ 13 ] .The PROBE study , which included more than 6000 HCV infected patients , showed that SVR was marginally associated with subtype 1a ( OR 1.41 ; 95 % CI 1.0 - 2.03 ) [ 7 ] .", "label": "", "metadata": {}, "score": "48.101036"}
{"text": "Aims : To determine whether single nucleotide polymorphisms ( SNPs ) at the SLC29A1 gene could influence the probability of treatment response compared with other baseline and host genetic factors .", "label": "", "metadata": {}, "score": "48.11326"}
{"text": "The DIRECT trial ( Daily - Dose Consensus Interfer- on and Ribavirin : Efficacy of Combined Therapy trial ) was a phase 3 , open - label , multicentre study investi- gating daily CIFN in 343 previous non - responders to peg - IFN and RBV ( 113 ) .", "label": "", "metadata": {}, "score": "48.181656"}
{"text": "Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low - virus load .Yasuji Arase Department of Hepatology , Toranomon Hospital , Tokyo Intern Med 48:253 - 8 .", "label": "", "metadata": {}, "score": "48.319614"}
{"text": "Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low - virus load .Yasuji Arase Department of Hepatology , Toranomon Hospital , Tokyo Intern Med 48:253 - 8 .", "label": "", "metadata": {}, "score": "48.319614"}
{"text": "Boyanova Y , Pissaia A , Conti F , Soubrane O , Calmus Y. Recurrent hepatitis C after liver transplantation : Erythro- poietin allows maintenance of antiviral treatment .", "label": "", "metadata": {}, "score": "48.393654"}
{"text": "Table 2 : Treatment results in patients with genotype 1 depending on IL-28B gene polymorphism .The last two decades have seen major advances in HCV treatment options and patient management .", "label": "", "metadata": {}, "score": "48.481384"}
{"text": "PubMed View Article .Bruno S , Camm\u00e0 C , Di Marco V , et al .: Peginterferon alfa-2b plus ribavirin for na\u00efve patients with genotype 1 chronic hepatitis C : a randomized controlled trial .", "label": "", "metadata": {}, "score": "48.48427"}
{"text": "120 - 129 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. W. Fried , M. L. Shiffman , K. Rajender Reddy et al . , \" Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "48.48678"}
{"text": "Using FACT , we could confirm whether the needle tip inserted at the target assuming enough coagulative necrosis area from all angles in all lesions .", "label": "", "metadata": {}, "score": "48.5494"}
{"text": "Further investigation is required to clarify whether these factors may contribute to SVR and develop novel individualized treatment algorithm .[ Show abstract ] [ Hide abstract ] ABSTRACT : Standard - dose ribavirin is crucial for the standard - of - care treatment of chronic hepatitis C virus ( HCV ) infection .", "label": "", "metadata": {}, "score": "48.660614"}
{"text": "Clin Microbiol Rev 2000 ; 13 : 223 - 35 .Boulestin A , Kamar N , Sandres - Saune K , et al .Twenty - four hour kinetics of hepatitis C virus and antiviral effect of alpha - interferon .", "label": "", "metadata": {}, "score": "48.73479"}
{"text": "Two of these patients had genotype 2 and 3 had genotype 3 .Mecenate et al .Page 4 .None of the baseline characteristics , including HCV genotype , were significantly associated with relapse .", "label": "", "metadata": {}, "score": "48.85847"}
{"text": "Clin Infect Dis 2001 ; 32 : 492 - 7 .Chung RT , Andersen J , Volberding P , et al .Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV - coinfected persons .", "label": "", "metadata": {}, "score": "48.98282"}
{"text": "Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005 ; 50 : 727 - 32 .", "label": "", "metadata": {}, "score": "49.03727"}
{"text": "Alberti AB , Belli LS , Airoldi A , et al .Combined therapy with interferon and low - dose ribavirin in posttransplantation recurrent hepatitis C : a pragmatic study .", "label": "", "metadata": {}, "score": "49.06377"}
{"text": "Our results are also in agreement with those reported by Mangia et al .[ 4 ] and by Dalgard et al.[18 ] , in which Table 2 Patients characteristics according to achievement of rapid virological response .", "label": "", "metadata": {}, "score": "49.079796"}
{"text": "\"Clinical studies show that CIFN is effective for HCV infection [ 15,16].Furthermore , several large multi - centre studies showed that patients with hepatitis C who do not respond to ordinary IFN - alpha therapy may benefit from re - administration of CIFN [ 17,18].", "label": "", "metadata": {}, "score": "49.116936"}
{"text": "They were assigned randomly to the derivation and confirmatory groups .SNPs related to the IL28B , ITPA and SLC29A1 genes were genotyped using real - time detection polymerase chain reaction .", "label": "", "metadata": {}, "score": "49.18559"}
{"text": "PegIntrust is a Belgian community based trial evaluating the sustained virological response .Patients and Methods : Observational study of 219 patients receiving pegylated interferon alfa-2b ( 1.5 \u03bcg / kg / wk ) and weight - based ribavirin ( 800 - 1200 mg / day ) for 48 weeks .", "label": "", "metadata": {}, "score": "49.229443"}
{"text": "[ Reprinted from Journal of Hepatology , Cornberg M et al . 'Treatment with daily consensus interferon ( CIFN ) plus ribavirin in non - responder patients with chronic hepatitis C : a randomized open - label pilot study . '", "label": "", "metadata": {}, "score": "49.23529"}
{"text": "Mariko Kobayashi Research Institute for Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 78:60 - 7 .In conclusion , patients persistently infected with HBV genotype A fare better than those with genotype B or C. However , high levels of HBV DNA continue in those in whom HBeAg persists along with fibrosis in the liver ... .", "label": "", "metadata": {}, "score": "49.359375"}
{"text": "( 26 ) also found lower SVR rates with IFN - based therapies in US veterans infected with HCV genotype 1 vs. genotypes 2/3 ( 13 vs. 61 % respectively ) .", "label": "", "metadata": {}, "score": "49.402054"}
{"text": "Shakil AO , McGuire B , Crippin J , et al .A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002 ; 36 : 1253 - 8 .", "label": "", "metadata": {}, "score": "49.408035"}
{"text": "Several trials are assessing the efficacy of peg - IFN alone or with RBVas maintenance therapy for chronic hepatitis C ( 120 ) .The ongoing HALT - C trial is de- signed to determine the efficacy and safety of low - dose peg - IFN - a-2a 90mg / week for 3.5 years in chronic hepatitis C patients with bridging fibrosis or cirrhosis and persistent viraemia despite previous IFN therapy ( 121 ) .", "label": "", "metadata": {}, "score": "49.422783"}
{"text": "The reasons for different outcomes are poorly understood .There are a lot of factors such as viral kinetics , immune mechanisms , environmental factors , and patient - related factors which may be responsible for the various HCV - related outcomes .", "label": "", "metadata": {}, "score": "49.455135"}
{"text": "PubMed .Yu JW , Wang GQ , Sun LJ , Li XG , Li SC : Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin .", "label": "", "metadata": {}, "score": "49.490646"}
{"text": "Poynard T , Bedossa P , Chevallier M , et al .A comparison of three interferon alfa-2b regimens for the long - term treat- ment of chronic non - A , non - B hepatitis .", "label": "", "metadata": {}, "score": "49.501186"}
{"text": "In order to detect IL-28B gene polymorphism - rs12979860 genotype frequency we used molecular biology methods : classical DNA separation from blood samples by phenol , amplification by PCR , and standard sequencing by Big Dye ( Applied Biosystems ) .", "label": "", "metadata": {}, "score": "49.58921"}
{"text": "Predicting treatment response in hepatitis C virus Achieving viral negativity by week 12 of therapy is highly predictive of SVR ( 9 ) .In a retrospective analy- sis , the SVR rate at 72 weeks was 67 % among adults with chronic hepatitis C who achieved early virological response with peg - IFN - a-2a and RBV at week 12 ( HCV RNA negative or 2 log decrease ) ( 123 ) .", "label": "", "metadata": {}, "score": "49.67563"}
{"text": "Predicting sustained virological responses in chronic hepatitis C pa- tients treated with peginterferon alfa-2a ( 40KD)/ribavirin .J Hepatol 2005 ; 43 : 425 - 33 .", "label": "", "metadata": {}, "score": "49.681473"}
{"text": "PubMed View Article .Rumi MG , Aghemo A , Prati GM , et al .: Randomized study of peginterferon alfa2a plus ribavirin vs peginterferon alfa2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010 , 138 : 108 - 115 .", "label": "", "metadata": {}, "score": "49.682205"}
{"text": "Kokoglu OF , Ucmak H , Hosoglu S , et al .Efficacy and tolerability of pegylated - interferon alpha-2a in hemodialy- sis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006 ; 21 : 575 - 80 .", "label": "", "metadata": {}, "score": "49.72255"}
{"text": "Intuitively , treatment earlier rather than later is desirable .Prediction of non - response is possible after a single dose of IFN in patients infected with HCV ( 28 , 127 ) .", "label": "", "metadata": {}, "score": "49.83142"}
{"text": "Abbott KC , Bucci JR , Matsumoto CS , et al .Hepatitis C and renaltransplantation in the era of modern immunosuppres- sion .J Am Soc Nephrol 2003 ; 14 : 2908 - 18 .", "label": "", "metadata": {}, "score": "49.88182"}
{"text": "Therapeutic options for treatment - resistant patients are limited , but retreatment with peg - IFN plus RBVor CIFN can produce SVR in complicated HCV infec- tions .", "label": "", "metadata": {}, "score": "49.942642"}
{"text": "To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg / day ... .Influence of amino - acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b .", "label": "", "metadata": {}, "score": "49.99508"}
{"text": "View Article .Knodell RG , Ishak KG , Black WC , et al .: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis .", "label": "", "metadata": {}, "score": "49.99601"}
{"text": "Teuber G , Kallinowski B , Niederau C , et al .Retreatment with pegylated interferon - alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin [ abstract].", "label": "", "metadata": {}, "score": "50.091038"}
{"text": "Laboratory parameters disorders ( thalassemia major , sickle cell anemia or G6PD deficit ) .Patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV infection including and not restricted to protease or polymerase inhibitors , .", "label": "", "metadata": {}, "score": "50.143745"}
{"text": "Abstract 96 .Sanchez - Tapias JM , Diago M , Escartin P , et al . Peginterfer-on - alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treat- ment .", "label": "", "metadata": {}, "score": "50.151"}
{"text": "Liver Transpl 2002 ; 8 : 350 - 5 . EversonGT , HoefsJC , SeeffLB , etal .Impactofdiseaseseverity on outcome of antiviral therapy for chronic hepatitis C : lessons from the HALT - C trial .", "label": "", "metadata": {}, "score": "50.249306"}
{"text": "Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients .Miharu Hirakawa Department of Hepatology , Toranomon Hospital , Tokyo Intern Med 47:1637 - 43 .", "label": "", "metadata": {}, "score": "50.25319"}
{"text": "Interferon monotherapy for dialysis patients with chronic hepatitis C : an analysis of the literature on efficacy and safety .Am J Gastroenterol 2003 ; 98 : 1610 - 5 .", "label": "", "metadata": {}, "score": "50.359543"}
{"text": "B\u00a8 ocher WO , Schuchmann M , Link R , et al .Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon - alpha therapy .", "label": "", "metadata": {}, "score": "50.59108"}
{"text": "Therret E , Pol S , Legendre C , Gagnadoux MF , Cavalcanti R , Kreis H. Low - dose recombinant leukocyte interferon - alpha treatment of hepatitis C viral infection in renal transplant recipients .", "label": "", "metadata": {}, "score": "50.793606"}
{"text": "The effect of fibrosis score and washout period in this study may require further investigation .Treatment duration is critical in complicated chronic hepatitis C infection .", "label": "", "metadata": {}, "score": "50.81372"}
{"text": "Perz JF , Armstrong GL , Farrington LA , Hutin YJ , Bell BP .The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide .", "label": "", "metadata": {}, "score": "50.82287"}
{"text": "All quantifications were performed at one central laboratory .HCV - RNA analysis was performed at week 4 , at the end of treatment ( 12 or 24 weeks ) and 24 weeks after the end of treatment .", "label": "", "metadata": {}, "score": "50.828888"}
{"text": "Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in treatmentof recurrent patients with recurrent hepatitis C virus infection post- transplantation .Am J Transplant 2007 ; 7 : 448 - 53 .", "label": "", "metadata": {}, "score": "50.861404"}
{"text": "Norio Chihara Department of Hepatology , Toranomon Hospital , Tokyo Intern Med 46:1847 - 51 .Genotype H , the newest type of hepatitis B , could be the type which shows a poor response to lamivudine .", "label": "", "metadata": {}, "score": "50.995956"}
{"text": "Bizollon T , Adham M , Pradat P , et al .Triple antiviral therapy with amantadine for IFN - ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplanta- tion 2005 ; 79 : 325 - 9 .", "label": "", "metadata": {}, "score": "51.081955"}
{"text": "Miglioresi L , Bacosi M , Russo F , et al .Consensus interferon versus interferon - alpha 2b plus ribavirin in patients with relapsing HCV infection .", "label": "", "metadata": {}, "score": "51.1026"}
{"text": "Data support treating patients who have chronic hepatitis C and are awaiting kidney transplantation ( 90 , 91 ) , improving both renal histology and biochem- ical markers of renal function ( 90 ) .", "label": "", "metadata": {}, "score": "51.116196"}
{"text": "Twenty eight per cent of patients with collagenous colitis and 26 % of patients with lymphocytic colitis had overlapping but less pronounced histological features .Both groups were equal in terms of age , use of aspirin and non - steroidal anti - inflammatory drugs , associated autoimmune conditions , arthritis , diarrhoea , and abdominal pain .", "label": "", "metadata": {}, "score": "51.183228"}
{"text": "Establishment of hepatitis C virus replicon cell lines possessing interferon- resistant phenotype .Biochem Biophys Res Commun 2004 ; 323 : 299 - 309 .Zein NN .", "label": "", "metadata": {}, "score": "51.20412"}
{"text": "ClinicalTrials.gov Identifier : NCT01342003 .Keywords .Genotype 1a HCV genotype 1 subtypes Sustained virological response Antiviral therapy Pegylated interferon .Background .Extensive research has shown that patients infected with HCV genotype 1 have a lower rate of viral response than those infected with genotype 2 or 3 .", "label": "", "metadata": {}, "score": "51.284058"}
{"text": "J Viral Hepat 2003 ; 10 : 37 - 42 .Liver International ( 2007 ) 1306 c ?2007 The Authors .Journal compilation c ?", "label": "", "metadata": {}, "score": "51.37255"}
{"text": "Virol .\u00a9 2013 Wiley Periodicals , Inc. .Polymorphisms in the human IL28B gene and amino acid substitutions in the core and interferon sensitivity - determining region ( ISDR ) in NS5A of HCV genotype 1b ( G1b ) were also shown to strongly affect the outcome of Peg - IFN plus RBV therapy .", "label": "", "metadata": {}, "score": "51.424026"}
{"text": "After transcatheter arterial chemoembolization or infusion chemotherapy using miriplatin as a sustained - release suspension in iodized oil and/or gelatin sponge , we performed RFA .", "label": "", "metadata": {}, "score": "51.50812"}
{"text": "J Hepatol 2003 , 39:655 - 656 .Neumann AU , Lam NP , Dahari H , Gretch DR , Wiley TE , Layden TJ , Perelson AS : Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon - alpha therapy .", "label": "", "metadata": {}, "score": "51.514835"}
{"text": "Alric L , Duffaut M , Selves J , et al .Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic Liver International ( 2007 ) c ?", "label": "", "metadata": {}, "score": "51.59011"}
{"text": "975 - 982 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. P. Manns , J. G. McHutchison , S. C. Gordon et al . , \" Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "51.707684"}
{"text": "2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard 1297 Liver International ISSN 1478 - 3223 .Page 2 . patients infected with HCV who are at risk for conti- nued hepatic injury is substantial .", "label": "", "metadata": {}, "score": "51.740944"}
{"text": "Rossi P , Bertani T , Baio P , et al .Hepatitis C virus - related cryoglobulinemic glomerulonephritis : long - term remission after antiviral therapy .", "label": "", "metadata": {}, "score": "51.75138"}
{"text": "Risk factors for infection include intravenous and intranasal drug use , nonsterile tattooing , manicure and pedicure procedures , as well as virus transmission vertically from mother to child , and during sexual intercourse .", "label": "", "metadata": {}, "score": "51.83636"}
{"text": "However , the effect of previous interferon therapy did not influence the EVR rate in both groups .Further investigation is necessary , to compare the SVR rate , adverse events , and those in extended combination therapy between the two groups .", "label": "", "metadata": {}, "score": "51.87422"}
{"text": "Nicot F , Alric L , Barange K , et al .: Influence of genotype 1 subtypes on the virus response to Peg interferon alpha-2a plus ribavirin therapy .", "label": "", "metadata": {}, "score": "51.919415"}
{"text": "- infection is associated with substantial morbidity and mortality , including end - stage liver disease , which is the leading cause of death in the hospitalized HIV population ( 54 ) .", "label": "", "metadata": {}, "score": "51.937607"}
{"text": "Zeuzem S , Lee JH , Franke A , R\u00fcster B , Pr\u00fcmmer O , Herrmann G , Roth WK : Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa .", "label": "", "metadata": {}, "score": "51.979218"}
{"text": "Evaluating 24-h HCV kinetics , Boulestin et al .( 24 ) noted a better response to antiviral therapy when Table 1 .Natural history of hepatitis C virus ( HCV ) infection .", "label": "", "metadata": {}, "score": "52.116158"}
{"text": "Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C .Yasuji Arase Department of Hepatology , Toranomon Hospital , Tokyo , Japan Intervirology 51:1 - 6 .", "label": "", "metadata": {}, "score": "52.15532"}
{"text": "In this retrospective study , we investigated the efficacy and predictors of response to 6-month IFN therapy ... .[ Corticosteroid withdrawal therapy in patients with chronic hepatitis B virus infection ] .", "label": "", "metadata": {}, "score": "52.270004"}
{"text": "Full - text \u00b7 Article \u00b7 Oct 2010 \u00b7 Liver international : official journal of the International Association for the Study of the Liver .Considering these high response rates , several recent randomized trials have assessed whether shorter treatment ( 12 - 16 weeks ) could be cost - effective in these patients .", "label": "", "metadata": {}, "score": "52.3859"}
{"text": "Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non - Hispanic whites .N Engl J Med 2004 ; 350 : 2265 - 71 .", "label": "", "metadata": {}, "score": "52.48222"}
{"text": "\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Consensus interferon ( CIFN ) is a newly developed type I interferon .Efficacy was assessed by normalization of serum alanine transaminase ( ALT ) levels and the non - detectability of serum hepatitis B virus DNA or HBeAg at the end of treatment and 24 weeks after stopping treatment .", "label": "", "metadata": {}, "score": "52.512215"}
{"text": "2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard Difficult - to - treat HCV patients Kemmer and Neff .Page 5 .One pilot study in 24 post - transplantation patients who did not respond to previous IFN - RBV therapy found that adding amantadine to IFN and RBV led to an SVR rate of 33 % ( 73 ) .", "label": "", "metadata": {}, "score": "52.63962"}
{"text": "The investigators concluded that CIFN should be considered for treatment - na\u0131 \u00a8ve patients , particularly those with high viral loads or genotype 1 infection ( 108 ) .", "label": "", "metadata": {}, "score": "52.69624"}
{"text": "Control Clin Trials 1996 ; 17 : 123 - 9 .Terranova R , Luca S. Treatment of chronic hepatitis C with lymphoblastoid interferon alpha in elderly patients .", "label": "", "metadata": {}, "score": "52.72085"}
{"text": "Many patients have mild disease at presentation but not all of them will develop advanced liver disease .However , the identification of these patients with mild hepatitis C who will show progressive disease is difficult and is based on histological criteria and the assessment of co - factors ( age , alcohol intake , steatosis ) .", "label": "", "metadata": {}, "score": "52.966484"}
{"text": "Nine of 13 ( 69 % ) prior partial responders and none of 10 ( 0 % ) prior null responders achieved SVR .The IL28B SNP still remained informative as a predictor of SVR to 24-week telaprevir - based triple combination therapy for East Asian patients infected with HCV genotype 1b .", "label": "", "metadata": {}, "score": "52.971436"}
{"text": "PubMed View Article .Rosina F , Tosti ME , Borghesio E , et al .: PEG - IFN for chronic hepatitis C in clinical practice : the prospective phase of the AIFA study .", "label": "", "metadata": {}, "score": "52.993134"}
{"text": "In the study of Lagging et al .[19 ] treat- ment for 12 weeks in HCV infection with genotype 2 or 3 was inferior to 24 weeks of treatment .", "label": "", "metadata": {}, "score": "52.995037"}
{"text": "No baseline characteristic was associated with relapse .In HCV patients with genotype 2 or 3 , 12-week combination therapy is as efficacious as 24-week therapy and several independent covariates were predictive of SVR .", "label": "", "metadata": {}, "score": "52.99694"}
{"text": "The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2 ... .Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan : comparison with breakthrough hepatitis during long - term treatment .", "label": "", "metadata": {}, "score": "53.008865"}
{"text": "J Hepatol 2004 , 40:993 - 999 .Hepatology 2004 , 40(Suppl 1):725A-725A , abstract .Neumann AV , Zeuzem S , Ferrari C , Lurie Y , Negro F , Germanidis G : DITTO- HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2 - 3 patients treated with Peg - IFN - alfa-2a and ribavirin .", "label": "", "metadata": {}, "score": "53.084335"}
{"text": "The efficacy of short - term interferon - beta therapy for chronic hepatitis C patients with low virus load .Yusuke Kawamura Department of Hepatology , Toranomon Hospital , Tokyo Intern Med 47:355 - 60 .", "label": "", "metadata": {}, "score": "53.105335"}
{"text": "Therefore , adequate monitoring of patients is important throughout ther- apy as it allows identification of patients with inade- quate treatment response who may benefit from early introduction of alternative therapies .", "label": "", "metadata": {}, "score": "53.10943"}
{"text": "( 110 ) con- ducted an open - label pilot study of CIFN and RBV in 77 patients who did not respond to standard IFN regimens ( 90 % of patients had HCV genotype 1 ) .", "label": "", "metadata": {}, "score": "53.206818"}
{"text": "A total of 146 Japanese genotype 1b chronic hepatitis C patients were enrolled in this prospective , multicenter study and received a 24-week regimen of triple therapy .", "label": "", "metadata": {}, "score": "53.21719"}
{"text": "The likelihood of SVR was significantly lower among those with high baseline viraemia ( HCV Liver International ( 2007 ) c ?2007 The Authors .", "label": "", "metadata": {}, "score": "53.220394"}
{"text": "Adherence to treatment was assessed using patient diaries .Virology HCV - RNA determination was performed with the COBAS Amplicore HCV test ( lower detection level 50 UI / ml ) .", "label": "", "metadata": {}, "score": "53.301613"}
{"text": "Shiffman ML .Chronic hepatitis C : treatment of pegylated interferon / ribavirin nonresponders .Curr Gastroenterol Rep 2006 ; 8 : 46 - 52 .", "label": "", "metadata": {}, "score": "53.31747"}
{"text": "Koyama R , Arase Y , Ikeda K , et al .Efficacy of interferon therapy in elderly patients with chronic hepatitis C. Inter- virology 2006 ; 49 : 121 - 6 .", "label": "", "metadata": {}, "score": "53.32454"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : We investigated \" Response - guided therapy \" 48 weeks vs. 72 weeks in 250 Japanese chronic hepatitis C patients infected with genotype 1b and high viral load to peginterferon ( Peg - IFN ) \u03b1-2b plus ribavirin ( RBV ) .", "label": "", "metadata": {}, "score": "53.35212"}
{"text": "Factors include not predictive of sustained viral response : age , gender , sources of infection , presence of icterus , alanine aminotransferase peak , bilirubin peak , incubation period , presence of hepatitis C virus antibodies at presentation , or genotypes .", "label": "", "metadata": {}, "score": "53.360336"}
{"text": "Patients without a RVR continued with 24-weeks ' combination therapy ( group B ) .HCV RNA was monitored at weeks 4 , 8 , 12 , and 24 , and at week 24 post - treatment .", "label": "", "metadata": {}, "score": "53.49828"}
{"text": "Patients without a RVR continued with 24-weeks ' combination therapy ( group B ) .HCV RNA was monitored at weeks 4 , 8 , 12 , and 24 , and at week 24 post - treatment .", "label": "", "metadata": {}, "score": "53.49828"}
{"text": "The aim of this study was to evaluate the efficacy of lamivudine therapy in Japanese patients with cirrhosis , and to evaluate the clinical course after the emergence of YMDD mutants ... .", "label": "", "metadata": {}, "score": "53.51775"}
{"text": "BACKGROUND AND AIMS :It is not known whether lymphocytic colitis and collagenous colitis represent different clinical entities or constitute part of a spectrum of disease .", "label": "", "metadata": {}, "score": "53.52317"}
{"text": "All the baseline characteristics of the 388 patients are reported in Table 1 .Virological response .A total of 18 genotype 1a and 16 genotype 1b patients discontinued all treatments at some time during the study owing due adverse events ( Figure 1 ) .", "label": "", "metadata": {}, "score": "53.558804"}
{"text": "Norio Akuta Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Scand J Gastroenterol 40:688 - 96 .The long - term effects of multi - course interferon ( IFN ) monotherapy in patients infected with hepatitis C virus ( HCV ) are still unclear ... .", "label": "", "metadata": {}, "score": "53.675644"}
{"text": "Conclusion .Dual antiviral therapy is more effective against HCV subtype 1a than against subtype 1b and this difference is independent of other factors that may favour viral clearance .", "label": "", "metadata": {}, "score": "53.7614"}
{"text": "All the patients who withdrew from the study and with HCV - RNA detectable at 24 weeks after the end of the treatment , were defined as non - responders .", "label": "", "metadata": {}, "score": "53.78045"}
{"text": "Norio Akuta Department of Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 80:1354 - 62 .A matched case - controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan : amino acid substitutions in HCV core region as predictor of sustained virological response .", "label": "", "metadata": {}, "score": "53.80126"}
{"text": "Decompensated liver disease , or history of decompensated liver disease , .Clinical evidence of significant or unstable cardiovascular disease , chronic pulmonary disease , history or evidence of retinopathy or clinically significant ophthalmological disorder .", "label": "", "metadata": {}, "score": "53.80303"}
{"text": "Jo YW , Youn YS , Lee SH , et al .Long - acting interferon - alpha 2a modified with a trimer - structured polyethylene glycol : preparation , in vitro bioactivity , in vivo stability and pharmacokinetics .", "label": "", "metadata": {}, "score": "53.96351"}
{"text": "J Virol 1992 ; 66 : 3225 - 9 .Weiner AJ , Brauer MJ , Rosenblatt J , et al .Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins .", "label": "", "metadata": {}, "score": "53.978447"}
{"text": "Narayanan Menon KV , Poterucha JJ , El - Amin OM , et al .Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin : lessons on tolerability and efficacy .", "label": "", "metadata": {}, "score": "53.9946"}
{"text": "Introduction .With the standard treatment of chronic hepatitis C , sustained virological response ( SVR ) can be achieved only in half of all patients .", "label": "", "metadata": {}, "score": "54.027077"}
{"text": "In our study more genotype 1b than genotype 1a patients relapsed after treatment although the difference was not statistically significance .This difference could have been due to the higher percentage of slow responding patients in genotype 1b group than in genotype 1a group .", "label": "", "metadata": {}, "score": "54.029472"}
{"text": "Zein NN , Rakela EL , Krawitt KR , Reddy KR , Tominaga T , Persing DH : Hepatitis C virus genotypes in United States : epidemiology , pathogenicity , and response to interferon therapy .", "label": "", "metadata": {}, "score": "54.04222"}
{"text": "Group B : historical series of 16 patients with untreated acute hepatitis C virus .RESULTS :There was no significant difference between the two groups with regard to gender , age , icterus , alanine aminotransferase , or genotypes .", "label": "", "metadata": {}, "score": "54.06005"}
{"text": "Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders : a pilot study of 7 cases .Norio Akuta Department of Hepatology , Toranomon Hospital , Tokyo , Japan akuta gi umin ac jp Intervirology 53:188 - 92 .", "label": "", "metadata": {}, "score": "54.06739"}
{"text": "Kidney Int 1998 ; 53 : 1374 - 81 .Stehman - Breen CO , Emerson S , Gretch D , Johnson RJ .Risk of death among chronic dialysis patients infected with hepatitis C virus .", "label": "", "metadata": {}, "score": "54.085434"}
{"text": "Page 5 . a 12 to 14-week regimen of PEG - IFN - a-2b and ribavirin ( adjusted for weight ) was associated with a significant rate of SVR , in patients with genotype 2 or 3 who had achieved an RVR .", "label": "", "metadata": {}, "score": "54.08748"}
{"text": "Statistically significant .Liver International ( 2007 ) 1302 c ?2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard Difficult - to - treat HCV patients Kemmer and Neff .", "label": "", "metadata": {}, "score": "54.093704"}
{"text": "Hickman IJ , Clouston AD , MacDonald GA , et al .Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002 ; 51 : 89 - 94 .", "label": "", "metadata": {}, "score": "54.106136"}
{"text": "Double- dose peginterferon alfa-2b with weight - based ribavirin im- proves response for interferon / ribavirin non - responders with hepatitis C : final results of ' ' RENEW ' ' [ abstract].", "label": "", "metadata": {}, "score": "54.220634"}
{"text": "The SLC29A1 and IL28B SNPs were also significantly associated with rapid virological response .The SNP at the major ribavirin transporter ENT1 gene SLC29A1 was one of significantly independent factors influencing treatment response , although the impact on the prediction was small .", "label": "", "metadata": {}, "score": "54.23573"}
{"text": "Ou- zan et al .( 130 ) administered peg - IFN - a-2a 180mg/ week plus RBV 1g / week to 20 treatment - na\u0131 \u00a8ve pa- tients infected with HCV genotype 1 .", "label": "", "metadata": {}, "score": "54.307625"}
{"text": "No baseline characteristic was associated with relapse .Conclusion : In HCV patients with genotype 2 or 3 , 12-week combination therapy is as efficacious as 24-week therapy and several independent covariates were predictive of SVR .", "label": "", "metadata": {}, "score": "54.319237"}
{"text": "Maintenance therapy with low - dose peg - IFN may slow progression of fibrosis , and observation may be an appropriate option for patients with more mild hepatic histology ( 60 ) .", "label": "", "metadata": {}, "score": "54.418766"}
{"text": "HCV - RNA was measured using polymerase chain reaction ( PCR ) , AMPLICOR , version 2.0 ; Roche , USA .Viral load for genotype 1 patients was measured at baseline and at week 12 on treatment .", "label": "", "metadata": {}, "score": "54.44152"}
{"text": "Drug : BI 201335 .Drug : Pegylated Interferon - alpha ( IFN ) .Drug : Ribavirin ( RBV ) .Not Provided .Recruitment Information .", "label": "", "metadata": {}, "score": "54.46109"}
{"text": "The study was approved by a central ethic committee ( San Camillo Hospital Rome Italy ) .Results .The study included 388 patients ; of these 165 were infected with HCV genotype 1 subtype 1a ( 42.5 % ) and 223 with subtype 1b ( 57.5 % ) .", "label": "", "metadata": {}, "score": "54.50429"}
{"text": "Drug : Pegylated Interferon - alpha ( IFN ) .Drug : Ribavirin ( RBV ) .Drug : Placebo .Experimental :BI201335 12 weeks . patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN / RBV for 48 weeks .", "label": "", "metadata": {}, "score": "54.537125"}
{"text": "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection .N Engl J Med 2002 ; 347 : 975 - 82 .Manns MP , Mchutchison JG , the International Hepatitis Interventional Therapy Group , et al .", "label": "", "metadata": {}, "score": "54.65975"}
{"text": "Liver Unit ASL RM /A .Infectious and Parasitic Diseases .References .McHutchison JG , Everson GT , Gordon SC , et al .", "label": "", "metadata": {}, "score": "54.696953"}
{"text": "Sulkowski MS , Thomas DL .Epidemiology and natural history of hepatitis C virus infection in injection drug users : implications for treatment .Clin Infect Dis 2005 ; 40(Suppl .", "label": "", "metadata": {}, "score": "54.714195"}
{"text": "Little is known about variables inftuencing tbis anemia .Our study tried to search for these variables in a large group of patients with hepatitis C treated with the combination therapy .", "label": "", "metadata": {}, "score": "54.716244"}
{"text": "These factors influence SVR rates in hepatitis C patients and could have played a role as well in the difference from virologic responses .Our study is the first study in Latvia and Baltics done on interleukin B28 gene polymorphism with findings similar to other studies involving Caucasian patients .", "label": "", "metadata": {}, "score": "54.7598"}
{"text": "Mutations of polymerase , precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy .Fumitaka Suzuki Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 8470 , Japan J Hepatol 37:824 - 30 .", "label": "", "metadata": {}, "score": "54.767757"}
{"text": "Torriani FJ , Ribeiro RM , Gilbert TL , et al .Hepatitis C virus ( HCV ) and human immunodeficiency virus ( HIV ) dy- namics during HCV treatment in HCV / HIV coinfection .", "label": "", "metadata": {}, "score": "54.774754"}
{"text": "Anticarcinogenic impact of interferon on patients with chronic hepatitis C : a large - scale long - term study in a single center .Kenji Ikeda Department of Gastroenterology , Toranomon Hospital , Toranomon 2 2 2 , Minato ku , Tokyo 105 8470 , Japan Intervirology 49:82 - 90 .", "label": "", "metadata": {}, "score": "54.921867"}
{"text": "Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection .N Engl J Med 2009 , 360 : 1827 - 1838 .PubMed View Article .", "label": "", "metadata": {}, "score": "55.01818"}
{"text": "Exceptions may include patients with HCV - associated glomerulonephritides to prevent graft loss .Patients with advanced fibrosis may also receive treatment to prevent death from liver- related complications .", "label": "", "metadata": {}, "score": "55.149464"}
{"text": "50 % of patients ; however , a significant number of patients do not respond to therapy or relapse following treatment discontinuation .Several viral , hepatic and patient - related factors influence response to IFN therapy ; many of these factors can not be modified to improve long - term outcomes .", "label": "", "metadata": {}, "score": "55.21411"}
{"text": "No serious adverse events were observed .RFA using FACT contributed more accurate insertion for HCC .Therefore , FACT would be a more useful tool for RFA .", "label": "", "metadata": {}, "score": "55.216766"}
{"text": "Layden - Almer JE , Ribeiro RM , Wiley T , Perelson AS , Layden TJ .Viral dynamics and response differences in HCV - infected African American and white patients treated with IFN and ribavirin .", "label": "", "metadata": {}, "score": "55.21871"}
{"text": "Long - term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection : emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open - cohort study .", "label": "", "metadata": {}, "score": "55.267105"}
{"text": "Pegylated interferon alpha-2a 180 mcg weekly plus standard dose ribavirin 100 - 1200 mg / day for 48 weeks .Drug : Pegylated interferon alpha-2a .", "label": "", "metadata": {}, "score": "55.288437"}
{"text": "Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus .J Infect Dis 2000 ; 182 : 28 - 35 .Jessner W , Stauber R , Hackl F , et al .", "label": "", "metadata": {}, "score": "55.311127"}
{"text": "Multiple logistic regression analysis for a sustained virological response identified the IL28B TT genotype , low \u03b1 - fetoprotein levels , non - responders , and a rapid virological response .", "label": "", "metadata": {}, "score": "55.362682"}
{"text": "Interleukin-28B ( IL-28B ) , named also as interferon \u03bb -3 , has been shown to be involved in the control of HCV infection , and the genetic polymorphism of the encoding IL-28B gene may determine the clearance of HCV .", "label": "", "metadata": {}, "score": "55.37963"}
{"text": "Weight - based dosing of antiviral medications also becomes an important consideration in patients with higher body mass indices ( 52 ) .Hepatitis C virus / human immunodeficiency virus co - infection An estimated 1 million individuals are human immu- nodeficiency virus ( HIV ) positive in the United States alone , and as many as 300000 are said to be co- infected with HCV ( 53 ) .", "label": "", "metadata": {}, "score": "55.39041"}
{"text": "Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999 ; 30 : 787 - 93 .Conjeevaram HS , Fried MW , Jeffers LJ , et al .", "label": "", "metadata": {}, "score": "55.453953"}
{"text": "Layden - Almer JE , Layden TJ .Viral kinetics in hepatitis C virus : special patient populations .Semin Liver Dis 2003 ; 23(Suppl .", "label": "", "metadata": {}, "score": "55.46048"}
{"text": "The rate of decline in the second phase is eight times faster in patients with genotype 2 or 3 compared with patients with genotype 1 [ 7,8].", "label": "", "metadata": {}, "score": "55.476288"}
{"text": "Bacon B , Regev A , Ghalib R , et al .Use of daily interferon alfacon-1 ( Infergens , CIFN ) plus ribavirin ( RBV ) in pa- tients infected with hepatitis C ( HCV ) who are nonrespon- ders to previous pegylated interferon plus RBV therapy : 24-week data from the DIRECT trial [ abstract].", "label": "", "metadata": {}, "score": "55.502148"}
{"text": "Among individuals with chronic HCV infection , 15 - 20 % progress to end - stage liver disease ( 5 ) .Cirrhosis and hepatocellular carcinoma , in parti- cular , are life - threatening complications , with an estimated 42 % of cirrhosis and 48 % of liver cancer cases in the United States , Canada and Cuba attri- buted to chronic HCV infection ( 6 ) .", "label": "", "metadata": {}, "score": "55.527405"}
{"text": "Evidence suggests that a similar response rate may be obtained with shorter treatment periods , especially in patients with a rapid virological response ( RVR ) .", "label": "", "metadata": {}, "score": "55.59401"}
{"text": "A total of103 Japanese non - responders with genotype 1b chronic hepatitis C receivedtelaprevir - based therapy .Among them , 81 patients ( 50 partialand 31 null responders ) received T12PR24 and 22(7 partial and 15 null responders ) who agreed to the extended therapy received T12PR48 .", "label": "", "metadata": {}, "score": "55.657204"}
{"text": "Am J Kidney Dis 1995 ; 26 : 662 - 7 .Hammoud H , Haem J , Laurent B , et al .Glomerular disease during HCVinfection in renal transplantation .", "label": "", "metadata": {}, "score": "55.73456"}
{"text": "Journal compilation c ?2007 Blackwell Munksgaard 1309 Kemmer and Neff Difficult - to - treat HCV patients .Page 14 . hepatitis C with biochemical response : results of a rando- mized trial .", "label": "", "metadata": {}, "score": "55.86115"}
{"text": "Therefore , we can not exclude the possibility that our subtype 1a patients may have had a more favourable IL28B polymorphism profile than did the subtype 1b patients .", "label": "", "metadata": {}, "score": "55.897507"}
{"text": "Sustained virological response .The overall rate of SVR was 48.2 % .( Data not shown ) .Legend .SVR : sustained virological response , F : female , M : male , PegINF : pegylated interferon , BMI : body mass index , ALT : alanine aminotransferase value ( IU / ml ) ; RVR : rapid virological response .", "label": "", "metadata": {}, "score": "55.911217"}
{"text": "Lee WM , Reddy KR , the Consensus Interferon Study Group , et al .Early hepatitis C virus - RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998 ; 28 : 1411 - 5 .", "label": "", "metadata": {}, "score": "55.916695"}
{"text": "It is not known whether lymphocytic colitis and collagenous colitis represent different clinical entities or constitute part of a spectrum of disease .METHODS : Detailed clinical features and histological findings were compared in a large series of patients with confirmed lymphocytic and collagenous colitis .", "label": "", "metadata": {}, "score": "56.004234"}
{"text": "The slight efficacy advantage for peg - IFN was attenuated by the slight disadvantage in the rates of discontinuation and graft rejections .Adverse effects also compromise outcomes .", "label": "", "metadata": {}, "score": "56.05887"}
{"text": "In the analysis , two trials of CIFN 9 or 15 mg in treatment - na\u0131 \u00a8ve patients or non - responders/ relapsers were included for evaluation .", "label": "", "metadata": {}, "score": "56.125412"}
{"text": "RESULTS : 131 patients ( 94 male/37 female ) were reported .Mean age was 63 years + /- 13 .Diagnosis of hepatocellular carcinoma was made by surveillance in 47 ( 36 % ) patients .", "label": "", "metadata": {}, "score": "56.307755"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Efficacy and Safety of BI 201335 ( Faldaprevir ) in Combination With Pegylated Interferon - alpha and Ribavirin in Treatment - Experienced Genotype 1 Hepatitis C Infected Patients ( STARTverso 3 ) .", "label": "", "metadata": {}, "score": "56.31279"}
{"text": "Importantly , virological relapse rates are very low in dialysis patients who achieve an SVR before transplan- tation ( 91 ) .Pre - transplantation treatment may also prevent postoperative complications such as fibrosing cholestatic hepatitis ( 91 ) .", "label": "", "metadata": {}, "score": "56.412716"}
{"text": "Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha - fetoprotein in patients without hepatocellular carcinoma .", "label": "", "metadata": {}, "score": "56.572838"}
{"text": "Other explanations include an obesity - triggered inflammatory reaction that decreases response and impairs IFN absorption owing to high levels of sub- cutaneous fat ( 44 , 46 ) .", "label": "", "metadata": {}, "score": "56.68592"}
{"text": "Quantitative determination of HCVRNA ( TaqMan Roche Diagnostics ) .was performed before the treatment .The TaqMan value used to determine the response was 15 IU / ml .", "label": "", "metadata": {}, "score": "56.728302"}
{"text": "Currently , six major HCV genotypes with multiple subtypes are character- ized , and HCV subtypes 1a and 1b are isolated most often in the United States ( 23 ) .", "label": "", "metadata": {}, "score": "56.886597"}
{"text": "( 108 ) , 128 treatment - na\u0131 \u00a8ve patients with chronic HCV infection were randomized to receive CIFN 15 mg or IFN - a-2b 3MU three times weekly plus RBV 1000mg / day for 48 weeks .", "label": "", "metadata": {}, "score": "56.92231"}
{"text": "( 126 ) reported that the probability of a non - sustained response increases as the values for viral load and log10decline in viral load move further away from designated thresholds .", "label": "", "metadata": {}, "score": "56.95067"}
{"text": "Current standard of care treatment involves combination therapy with hopes of effective virus eradication resulting in a sustained virological response ( SVR ) and thereby stopping the progression of disease .", "label": "", "metadata": {}, "score": "57.125996"}
{"text": "BackgroundlAims : One of the major side eft'ects of the combination therapy for chronic hepatitis C is ribavirininduced hemolytic anemia .Little is known about variables inftuencing tbis anemia .", "label": "", "metadata": {}, "score": "57.168945"}
{"text": "Acknowledgment .This work was supported by European Social Fund .References .I. Tolmane , B. Rozentale , J. Keiss , F. Arsa , and A. Zvaigzne , \" Prevalence of viral hepatitis C in Latvia : a population based study , \" Medicina , vol .", "label": "", "metadata": {}, "score": "57.1764"}
{"text": "The majority of patients had evidence of bridging fibrosis or cirrhosis on biopsy , and the mean washout period was 485 - 535 days .Viral response was lower in patients with higher fibrosis scores .", "label": "", "metadata": {}, "score": "57.24718"}
{"text": "Common adverse effects of IFN and RBV therapy , such as depression and anaemia , are often amplified in patients also receiving antiretroviral therapy ( 55 ) , and the risk of drug - drug interactions is substantial .", "label": "", "metadata": {}, "score": "57.340897"}
{"text": "Akihito Tsubota Department of Gastroenterology , Toranomon Hospital , Minato ku , Tokyo , Japan J Med Virol 73:7 - 12 .The present study provides important information for the development of more effective and rational long - term lamivudine therapy for HBeAg - positive chronic hepatitis B patients infected exclusively with genotype .", "label": "", "metadata": {}, "score": "57.4803"}
{"text": "Knodell RG , Ishak KG , Black WC , Chen TS , Craig R , Kaplowitz N , Kiernan TW , Wollman J : Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis .", "label": "", "metadata": {}, "score": "57.55194"}
{"text": "PubMed .Cheng WS , Roberts SK , McCaughan G : Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing .", "label": "", "metadata": {}, "score": "57.557175"}
{"text": "Pawlotsky JM .Hepatitis C virus genetic variability : patho- genic and clinical implications .Clin Liver Dis 2003 ; 7 : 45 - 66 .", "label": "", "metadata": {}, "score": "57.59415"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : The drugs currently licensed for the treatment of hepatitis C are Peg - Interferon ( PEG - IFN ) and ribavirin .", "label": "", "metadata": {}, "score": "57.61812"}
{"text": "Virol .\u00a9 2013 Wiley Periodicals , Inc. .Of 140 patients who were enrolled in this study , 137 received 12-week telaprevir combined with 24-week pegylated interferon alpha-2b plus ribavirin and were subjected to the analysis .", "label": "", "metadata": {}, "score": "57.633415"}
{"text": "Ong JP , Younossi ZM , Speer C , Olano A , Gramlich T , Boparai N. Chronic hepatitis C and superimposed nonalco- holic fatty liver disease .", "label": "", "metadata": {}, "score": "57.71927"}
{"text": "Patients with depression and nauseas lost more weight .Conclusion : Hepatitis C patients on antiviral treatment lose weight and show malnutrition signs evaluated through the fat and proteic stores meas urements .", "label": "", "metadata": {}, "score": "57.740063"}
{"text": "For each group , the influence of the match MELD on the probability of receiving a transplant was studied ( Cox proportional hazards model ) .", "label": "", "metadata": {}, "score": "57.80989"}
{"text": "Our results suggest that long - term lamivudine therapy improves long - term prognosis , especially when additional treatment for breakthrough hepatitis is used ... .", "label": "", "metadata": {}, "score": "57.879807"}
{"text": "Patients were classified into \" rapid virological response \" and \" non - rapid virological response \" groups .The non - rapid virological response group was further divided into a \" virological response at 8 weeks \" ( serum HCV RNA disappearance after 8 weeks of therapy ) and a \" non - virological response at 8 weeks \" group .", "label": "", "metadata": {}, "score": "57.899445"}
{"text": "Histological improvements after a three - year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop .Yoshiyuki Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Intervirology 46:164 - 70 .", "label": "", "metadata": {}, "score": "58.127884"}
{"text": "These subtypes are also predominant in Europe and subtype 1b is responsible for up to 73 % of HCV infection in Japan .Zein et al .", "label": "", "metadata": {}, "score": "58.2529"}
{"text": "The individual calculated dose should be administered for each patient beginning on the first day of treatment .Both groups will receive combination treatment with peginterferon alpha 2a 180 mcg / week for a total of 48 weeks .", "label": "", "metadata": {}, "score": "58.265327"}
{"text": "Optimal Ribavirin doses are essential to achieve SVR ( sustained virological response ) .A recent trial showed significantly higher sustained virological response ( SVR ) in patients receiving 15.2 mg / kg / day of Ribavirin compared with 13.3 mg / kg / day .", "label": "", "metadata": {}, "score": "58.276466"}
{"text": "Shiffman ML , Suter F , Bacon BR , Nelson D , Harley H , Sol\u00e1 R , Shafran SD , Barange K , Lin A , Soman A , Zeuzem S : ACCELERATE InvestigatorsPeginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 .", "label": "", "metadata": {}, "score": "58.34301"}
{"text": "Factors associated with HCC recurrence have to be identified .Background : Liver allocation in Eurotransplant ( ET ) is based on the MELD score .", "label": "", "metadata": {}, "score": "58.41217"}
{"text": "However , research focusing on the efficacy and safety of antiviral therapy in the older population is limited to a few small , single - centre studies ( 41 - 43 ) .", "label": "", "metadata": {}, "score": "58.424934"}
{"text": "Methods .Patients .A total of 11 regional centres affiliated with the CLEO Group partecipate in the study between February 2007 and October 2010 .", "label": "", "metadata": {}, "score": "58.505817"}
{"text": "The cost for achieving ( CAS ) one sustained virological response was lowest with 36-week therapy .Prolongation of Peg - IFN - plus - ribavirin combination therapy to 36 weeks is suitable for achieving virological response at 8 weeks , given the high , sustained virological response rate and cost benefit .", "label": "", "metadata": {}, "score": "58.697067"}
{"text": "Up to 32.1 % of patients on mainte- nance dialysis are anti - HCV positive ( 75 - 78 ) , as are 6.8 % of adult cadaveric renal graft recipients ( 79 ) .", "label": "", "metadata": {}, "score": "58.707676"}
{"text": "Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B .Yasuji Arase Department of Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 79:1286 - 92 .", "label": "", "metadata": {}, "score": "58.735676"}
{"text": "The influence of hepatitis B virus genotype on the development of lamivudine resistance during long - term treatment .Norio Akuta Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 0001 , Japan J Hepatol 38:315 - 21 .", "label": "", "metadata": {}, "score": "58.739845"}
{"text": "All patients who acquired HCV before 1955 were infected with subtype 1b .Subtype 1a was introduced in the late 1950s and then , it became the most prevalent genotype [ 13 ] .", "label": "", "metadata": {}, "score": "58.836044"}
{"text": "Pawlotsky JM .Hepatitis C virus population dynamics during infection .Curr Top Microbiol Immunol 2006 ; 299 : 261 - 84 .Martell M , Esteban JI , Quer J , et al .", "label": "", "metadata": {}, "score": "59.042843"}
{"text": "Petrosillo N , Gilli P , Serraino D , et al .Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis .", "label": "", "metadata": {}, "score": "59.092236"}
{"text": "Yusuke Kawamura Department of Hepatology , Toranomon Hospital , Minato ku , Tokyo , Japan Am J Med 123:951 - 956 . e1 .This retrospective cohort study assessed the impact of diabetes mellitus on hepatocarcinogenesis and determined the predictors of hepatocarcinogenesis in noncirrhotic , interferon - treated patients with hepatitis C virus infection ... .", "label": "", "metadata": {}, "score": "59.110176"}
{"text": "Material and Methods .There were 159 chronic viral hepatitis C patients included in the study .All chronic viral hepatitis C patients who came to Infectology Center of Latvia for a hepatologist 's consultation were tested .", "label": "", "metadata": {}, "score": "59.16217"}
{"text": "Patients and methods Data were extracted from two Belgian observational databases .Results A total of 655 patients ( 387 HBV and 268 HCV ) were included .", "label": "", "metadata": {}, "score": "59.19429"}
{"text": "Yoshiyuki Suzuki Department of Hepatology , Toranomon Hospital , Takatsu ku , Kawasaki City , Japan Dig Dis Sci 55:2070 - 6 .Influence of human lymphocyte antigen ( HLA ) on the therapeutic response in autoimmune hepatitis ( AIH ) is not known ... .", "label": "", "metadata": {}, "score": "59.234703"}
{"text": "In both arms , ribavirin ( 1000 - 1200 mg orally per day ) was added at week 4 .However , response at the end of treatment and at 6 months follow - up was not different ( 53%vs 50 % , 41%vs 33 % ) .", "label": "", "metadata": {}, "score": "59.236763"}
{"text": "In both arms , ribavirin ( 1000 - 1200 mg orally per day ) was added at week 4 .However , response at the end of treatment and at 6 months follow - up was not different ( 53%vs 50 % , 41%vs 33 % ) .", "label": "", "metadata": {}, "score": "59.236763"}
{"text": "Liver International ( 2007 ) c ?2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard 1303 Kemmer and Neff Difficult - to - treat HCV patients .", "label": "", "metadata": {}, "score": "59.575195"}
{"text": "Additional criteria for exclusion were : pregnancy , lactation , impaired renal function , and other concurrent medical conditions of the liver differ- ent from HCV infection .", "label": "", "metadata": {}, "score": "59.617203"}
{"text": "Our main exclusion criteria will be : decompensated cirrhotic patients , HBV / HIV co - infection , evidence of hepatocellular carcinoma ( HCC ) , significant evolutive cardiovascular , pulmonary , renal or psychiatric disease , pregnancy / breast feeding or patients post liver transplantation and anemia .", "label": "", "metadata": {}, "score": "59.72701"}
{"text": "Results : In total , 108 patients ( 49.3 % ) had undetectable HCV RNA at the end of therapy , 91 ( 41.6 % ) attaining SVR .", "label": "", "metadata": {}, "score": "59.80818"}
{"text": "Bressler BL , Guindi M , Tomlinson G , Heathcote J. High body mass index is an independent risk factor for non-response to antiviral treatment in chronic hepatitis C. Hepatology 2003 ; 38 : 639 - 44 .", "label": "", "metadata": {}, "score": "59.932835"}
{"text": "Metabolic or autoimmune liver disease .Patients with evolutive diabetic or hypertensive retinopathy .Patients who are stable can be included but should be regularly followed during treatment .", "label": "", "metadata": {}, "score": "59.9865"}
{"text": "Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy .Yasuji Arase Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 8470 , Japan J Gastroenterol 39:455 - 60 .", "label": "", "metadata": {}, "score": "60.08271"}
{"text": "Drug : BI 201335 .Drug : Pegylated Interferon - alpha ( IFN ) .Drug : Ribavirin ( RBV ) .Experimental :BI201335 24 weeks . patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN / RBV for 48 weeks .", "label": "", "metadata": {}, "score": "60.093674"}
{"text": "Brief Summary .The aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN / RBV given for 48 weeks as compared to PegIFN / RBV alone in chronic GT-1 hepatitis C virus infected patients who failed a prior PegIFN / RBV treatment .", "label": "", "metadata": {}, "score": "60.105927"}
{"text": "Nephrol Dial Transplant 2001 ; 16 : 1669 - 74 .Pereira BJ , Natov SN , The New England Organ Bank Hepatitis C Study Group , et al .", "label": "", "metadata": {}, "score": "60.110207"}
{"text": "Background : Liver allocation in Eurotransplant ( ET ) is based on the MELD score .Interlaboratory MELD score differences in INR and creatinine determination have been reported .", "label": "", "metadata": {}, "score": "60.15535"}
{"text": "Yoshiyuki Suzuki Department of Hepatology , Toranomon Hospital , Takatsu ku , Kawasaki City , Japan J Gastroenterol Hepatol 24:429 - 35 .However , hepatitis B virus ( HBV ) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis ... .", "label": "", "metadata": {}, "score": "60.18596"}
{"text": "Achieving viral eradication is the goal of antiviral therapy and is defined by sustained virological re- sponse ( SVR ; Table 1 ) ( 5 , 8) .", "label": "", "metadata": {}, "score": "60.199215"}
{"text": "Liver International ( 2007 ) c ?2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard 1305 Kemmer and Neff Difficult - to - treat HCV patients .", "label": "", "metadata": {}, "score": "60.28601"}
{"text": "In addition , RBV is generally avoided in dialysis pati- ents , because it may induce haemolytic anaemia ( 98 ) .Two meta - analyses found that IFN monotherapy produced SVR rates of 33 - 39 % ( 92 , 99 ) .", "label": "", "metadata": {}, "score": "60.296967"}
{"text": "Total discontinuation , dose modification and adverse events related to antiviral treatment .Discussion .We have conducted a large observational study to assess the influence of viral subtype within HCV genotype 1 on the virological response to antiviral treatment in na\u00efve HCV patients .", "label": "", "metadata": {}, "score": "60.37783"}
{"text": "These factors were closely correlated with significant anemia .However , the model could not be constructed , because no patients with rs1127354 minor genotype CA / AA had significant anemia .", "label": "", "metadata": {}, "score": "60.51291"}
{"text": "140 , no .5 , pp .346 - 355 , 2004 .View at Google Scholar \u00b7 View at Scopus . A. Par , P. Kisfali , and B. Melegh , \" Cytokine ( IL-10 , IL-28B and LT - A ) gene polymorphisms in chronic hepatitis C virus infection , \" The International Journal of Clinical and Experimental Medicine , vol .", "label": "", "metadata": {}, "score": "60.53384"}
{"text": "To clarify reasons for discrepant results in the studies so far published , the recently discovered genetic variant near the interleukin 28B gene will be presented and its predictive role will be discussed .", "label": "", "metadata": {}, "score": "60.57473"}
{"text": "Clinical and virological features of non - breakthrough and severe exacerbation due to lamivudine - resistant hepatitis B virus mutants .Fumitaka Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan J Med Virol 78:341 - 52 .", "label": "", "metadata": {}, "score": "60.59099"}
{"text": "Abstract 1293 .Poynard T , Schiff EG , Terg R , et al .Sustained virologic response ( SVR ) in the EPIC3 trial : week twelve virology predicts SVR in previous interferon / ribavirin treatment failures receiving PEG - Intron / Rebetol ( PR ) weight based dosing ( WBD ) [ abstract].", "label": "", "metadata": {}, "score": "60.671505"}
{"text": "Yoshimasa Hashimoto Department of Hepatology , Toranomon Hospital , Minato ku , Tokyo , Japan J Med Virol 82:684 - 91 .Moreover , after the emergence of YMDD mutants , short latency to the emergence of YMDD mutant , mixed type mutants , and low baseline ALT level were associated with elevation of ALT or viral load ... .", "label": "", "metadata": {}, "score": "60.714348"}
{"text": "HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B .Fumitaka Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan J Med Virol 70:355 - 60 .", "label": "", "metadata": {}, "score": "60.741997"}
{"text": "Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon , ribavirin , and telaprevir .Fumitaka Suzuki Department of Hepatology , Toranomon Hospital , Tokyo , Japan Hepatology 53:415 - 21 .", "label": "", "metadata": {}, "score": "60.77571"}
{"text": "Harihara Y , Kurooka Y , Yanagisawa T , Kuzuhara K , Otsubo O , Kumada H. Interferon therapy in renal allograft recipi- ents with chronic hepatitis C. Transplant Proc 1994 ; 26 : 2075 .", "label": "", "metadata": {}, "score": "60.94916"}
{"text": "While we observed in dual antiviral therapy a better SVR of genotype 1a respect to genotype 1b patients , genotype 1a presents higher virologic failure respect to genotype 1b in patients treated with triple antiviral combination therapy including protease inhibitors Boceprevir or Telaprevir .", "label": "", "metadata": {}, "score": "61.006886"}
{"text": "Hiromi Saneto Department of Hepatology , Toranomon Hospital , Tokyo , Japan J Gastroenterol 43:975 - 81 .The aim of this retrospective study was to determine the incidence and characteristics of hepatocellular carcinoma ( HCC ) in hepatitis C virus ( HCV ) antibody - positive elderly patients with chronic hepatitis without cirrhosis ... .", "label": "", "metadata": {}, "score": "61.0129"}
{"text": "Methods : We ret- rospectively analysed all patients listed for OLT with HCC and underlying cirrhosis between 12/2006 and 12/2011 from all Belgian liver transplant centres .", "label": "", "metadata": {}, "score": "61.029793"}
{"text": "Importantly , rates of serious adverse events , dose reductions and discontinuations were similar between the groups , suggesting another mechanism for the observed effi- cacy difference .", "label": "", "metadata": {}, "score": "61.032692"}
{"text": "This individual variability may be due to single - nucleotide polymorphisms within the coding regions of cytokine genes .Cytokine genes are polymorphic , and some of these variants modify the production of the specific cytokines thereby affecting the host immune response .", "label": "", "metadata": {}, "score": "61.10728"}
{"text": "The significance of antiviral therapy for elderly patients with chronic hepatitis C virus ( HCV ) infection has not been elucidated ... .Virological response and hepatocarcinogenesis in lamivudine - resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil .", "label": "", "metadata": {}, "score": "61.169357"}
{"text": "Marie Matsuda Research Institute for Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 74:361 - 6 .Virological and biochemical relapse according to YMDD motif mutant type during long - term lamivudine monotherapy .", "label": "", "metadata": {}, "score": "61.219444"}
{"text": "Response to long - term lamivudine treatment in patients infected with hepatitis B virus genotypes A , B , and C .Mariko Kobayashi Research Institute for Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 78:1276 - 83 .", "label": "", "metadata": {}, "score": "61.25786"}
{"text": "Necessities of interferon therapy in elderly patients with chronic hepatitis C .Kenji Ikeda Department of Hepatology , Toranomon Hospital , Tokyo , Japan Am J Med 122:479 -", "label": "", "metadata": {}, "score": "61.30176"}
{"text": "Fontana et al .( 40 ) developed a model to estimate the probability of severe fibrosis in African American and white patients based on commonly available clinical and laboratory parameters .", "label": "", "metadata": {}, "score": "61.361446"}
{"text": "ChronichepatitisCisalsoassociated with mixed essential cryoglobulinaemia ( 83 ) , increasing post - transplantation morbidity byenhancing the riskof de novo or recurrent HCV - associated glomerulopathies ( 84 - 88 ) .", "label": "", "metadata": {}, "score": "61.423943"}
{"text": "Pegylation of IFN changes the drug 's pharmacokinetics , and maximum plasma concentra- tions persist over a longer period , half - life is extended and clearance is reduced ( 128 , 129 ) .", "label": "", "metadata": {}, "score": "61.479836"}
{"text": "Fabrizi F , Dulai G , Dixit V , Bunnapradist S , Martin P. Meta- analysis : interferonfor thetreatmentof chronichepatitisCin dialysis patients .Aliment Pharmacol Ther 2003 ; 18 : 1071 - 81 .", "label": "", "metadata": {}, "score": "61.56701"}
{"text": "When non - RVR cases with HCV - RNA reduction during 0 - 4 weeks less than 2 Log 10 IU / mL and that achieved LVR , total dose of RBV per body weight more than 3 g / kg and extended treatment to 72 weeks may increase SVR rate .", "label": "", "metadata": {}, "score": "61.593163"}
{"text": "Mean duration of symptoms before diagnosis was two months for lymphocytic colitis and four months for collagenous colitis .CONCLUSIONS : Collagenous and lymphocytic colitis are similar but not identical .", "label": "", "metadata": {}, "score": "61.714592"}
{"text": "The continuous production of these variants allows HCV to escape host defences and resist clear- ance by antiviral therapies ( 18 ) .Thus , patients who have minimal HCV complexity ( i.e. small quasispecies sequence ) are more likely to achieve SVR than patients with large HCV complexity and significant changes in the quasispecies composition ( 18 , 21 ) .", "label": "", "metadata": {}, "score": "61.771484"}
{"text": "The long - term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus ( HBV ) infection is still unclear ... .", "label": "", "metadata": {}, "score": "61.773167"}
{"text": "Norio Akuta Department of Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 80:1363 - 9 .Long - term outcome after interferon therapy in elderly patients with chronic hepatitis C .", "label": "", "metadata": {}, "score": "61.838425"}
{"text": "Liver International ( 2007 ) 1308 c ?2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard Difficult - to - treat HCV patients Kemmer and Neff .", "label": "", "metadata": {}, "score": "61.849907"}
{"text": "Yoshiyuki Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Intervirology 46:164 - 70 .The long - term effects of lamivudine and the influence of YMDD mutants on the histology of chronic hepatitis B are not known ... .", "label": "", "metadata": {}, "score": "61.996502"}
{"text": "These scores were found to be equally predictive in both groups of patients and may be useful in identifying difficult - to - treat patients in the African American cohort .", "label": "", "metadata": {}, "score": "62.031918"}
{"text": "Changing treatment paradigms : hepa- titis C virus in HIV - infected patients .AIDS Patient Care STDS 2007 ; 21 : 154 - 68 .", "label": "", "metadata": {}, "score": "62.064095"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : May 23 , 2011 ) .Alanine transaminase ( ALT ) normalisation : ALT in normal range 24 weeks after end of the originally planned treatment duration .", "label": "", "metadata": {}, "score": "62.089577"}
{"text": "One possible explanation is a high prevalence of HCV genotype 1 among African American patients ( 88 - 96 % ) ( 36 , 39 ) , but this can not fully explain the insufficient response .", "label": "", "metadata": {}, "score": "62.097687"}
{"text": "All patients who withdrew from the study were also defined as non - responders .The primary end point was sustained undetectable serum HCVRNA 24 weeks after the end of treatmen ( SVR ) .", "label": "", "metadata": {}, "score": "62.12631"}
{"text": "Neumann AU , Lam NP , Dahari H , Davidian M , Wiley TE , Mika BP , Perelson AS , Layden TJ : Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus .", "label": "", "metadata": {}, "score": "62.144463"}
{"text": "Although potentially beneficial , the cost , safety and risk of non - compliance could limit this approach .References 1 .Centers for Disease Control and Prevention .", "label": "", "metadata": {}, "score": "62.2143"}
{"text": "Methods : Belgian physicians were asked to report all chronically infected HBV patients during a one - year period .Using less restrictive criteria for ALT ( 1 - 2 ULN ) or HBV DNA ( 2,000 - 20,000 IU / mL ) , 93 unclassified patients were added to the group of inactive carriers .", "label": "", "metadata": {}, "score": "62.215565"}
{"text": "Changes in viremia levels over the first weeks of therapy correlate with the likelihood of the eradication of HCV , and undetectable viral levels at week 12 are predictive of a response after 48 weeks of therapy [ 9,10].", "label": "", "metadata": {}, "score": "62.312428"}
{"text": "Induction treatment could result in a faster early decline of the hepatitis C virus ( HCV ) load and a better response rate .After week 8 , interferon treatment in both arms was 3 MU s.c .", "label": "", "metadata": {}, "score": "62.35486"}
{"text": "Induction treatment could result in a faster early decline of the hepatitis C virus ( HCV ) load and a better response rate .After week 8 , interferon treatment in both arms was 3 MU s.c .", "label": "", "metadata": {}, "score": "62.35486"}
{"text": "After 4 weeks of treatment , the negative predictive value increased to 100 % with a viral drop threshold of 2.81log10copies/mL. Findings from a study by Carlsson et al .", "label": "", "metadata": {}, "score": "62.480145"}
{"text": "Illicit drug or alcohol abuse are associated with non - compliance , and adverse events prompt treatment discontinuation in up to 14 % of patients receiving peg - IFN regimens ( 2 ) .", "label": "", "metadata": {}, "score": "62.686455"}
{"text": "The addition of amantadine to RBV was also not superior to RBV in renal transplantation patients with chronic hepatitis C , perhaps because of the poor tolerability of both medications in patients with impaired renal function ( 101 ) .", "label": "", "metadata": {}, "score": "62.704723"}
{"text": "Although patients with advanced fibrosis or early - compensated cirrhosis generally have lower response rates , they can be successfully treated and may achieve SVR ( 30 ) .", "label": "", "metadata": {}, "score": "62.70929"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT01686789 .Hepatitis Hepatitis A Hepatitis C Hepatitis C , Chronic Hepatitis , Chronic Digestive System Diseases Enterovirus Infections Flaviviridae Infections Hepatitis , Viral , Human Liver Diseases Picornaviridae Infections RNA Virus Infections Virus Diseases .", "label": "", "metadata": {}, "score": "62.72684"}
{"text": "Active Comparator : Placebo / PegIFN / RBV . patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN / RBV for 48 weeks .", "label": "", "metadata": {}, "score": "62.795914"}
{"text": "Inclusion criteria : .Chronic hepatitis C genotype 1 infection , diagnosed at least 6 months prior to screening .Confirmed prior virological failure with an approved dose of PegIFN / RBV .", "label": "", "metadata": {}, "score": "63.066856"}
{"text": "Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG - IFN / RBV ... .Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia .", "label": "", "metadata": {}, "score": "63.156685"}
{"text": "Yoshiyuki Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan J Gastroenterol Hepatol 19:699 - 706 .The defining of the autoimmune hepatitis ( AIH ) and primary biliary cirrhosis ( PBC ) overlap syndrome as a separate clinicopathological entity has been controversial and temporally and geographically subjective ... .", "label": "", "metadata": {}, "score": "63.315777"}
{"text": "Control Clin Trials 2004 ; 25 : 472 - 92 .Pawlotsky J - M , Gish RG .Future therapies for hepatitis C. Antivir Ther 2006 ; 11 : 397 - 408 .", "label": "", "metadata": {}, "score": "63.368538"}
{"text": "Management of hepatitis C virus coinfection in HIV - infected persons .AIDS Read 2006 ; 16 : 313 - 20 .Bica I , McGovern B , Dhar R , et al .", "label": "", "metadata": {}, "score": "63.501503"}
{"text": "Introduction Nationwide studies comparing patients with hepatitis B and C virus ( HBV and HCV ) infections are mandatory for assessing changes in epidemiology .Introduction Nationwide studies comparing patients with hepatitis B and C virus ( HBV and HCV ) infections are mandatory for assessing changes in epidemiology .", "label": "", "metadata": {}, "score": "63.55755"}
{"text": "Transplantation 1994 ; 58 : 625 - 8 .Wong T , Lee SS .Hepatitis C : a review for primary care physicians .CMAJ 2006 ; 174 : 649 - 59 .", "label": "", "metadata": {}, "score": "63.618294"}
{"text": "In terms of the higher SVR on CC genotype patients from the study cohort when compared with Thompson et al . '2010 study , this cohort had younger patients with lower BMI 's , but with higher advanced fibrosis and steatosis rate .", "label": "", "metadata": {}, "score": "63.63347"}
{"text": "Ohnishi K , Matsuo S , Matsutani K , et al .Interferon therapy for chronic hepatitis C in habitual drinkers : comparison with chronic hepatitis C in infrequent drinkers .", "label": "", "metadata": {}, "score": "63.82949"}
{"text": "Rumi MG , Aghemo A , Prati GM : Comparative trials of peginterferon alfa-2a and peginterferon alfa-2b for chronic hepatitis C. J Viral Hepatol 2012 , 19 : 37 - 41 .", "label": "", "metadata": {}, "score": "63.87259"}
{"text": "Sarrazin C , Zeuzem S : Resistance to direct antiviral agents in patients with hepatitis C virus infection .Gastroenterology 2010 , 138 : 447 - 462 .", "label": "", "metadata": {}, "score": "63.880188"}
{"text": "Only biopsy with a length exceeding 1 cm and containing more than 6 portal tracts were evaluated .All the biopsy were graded by two indipendent observers and the evaluation was performed according to the Ishak score [ 15].", "label": "", "metadata": {}, "score": "63.99546"}
{"text": "Fontana RJ , Kleiner DE , Bilonick R , et al .Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection .", "label": "", "metadata": {}, "score": "64.123924"}
{"text": "Although the 12-week stopping rule is used to guide therapy , measures of absolute viral load and log decline in viral load earlier in the course of HCV therapy may more accurately predict an SVR as well as monotherapy and 97 % a non - response .", "label": "", "metadata": {}, "score": "64.125206"}
{"text": "Retreatment options for patients who have failed therapy are limited .Retreatment with peg - IFN has been successful in some patients who exhibit an inadequate response to conventional IFN treatment , particularly those who have relapsed .", "label": "", "metadata": {}, "score": "64.14633"}
{"text": "Subgroups of patients likely to take advantage of the addition of amantadine were not identified .Conclusions This large study definitely excludes the role of amantadine in addition of conventional combination therapy in the treatment of chronic hepatitis C patients .", "label": "", "metadata": {}, "score": "64.19362"}
{"text": "Subgroups of patients likely to take advantage of the addition of amantadine were not identified .Conclusions This large study definitely excludes the role of amantadine in addition of conventional combination therapy in the treatment of chronic hepatitis C patients .", "label": "", "metadata": {}, "score": "64.19362"}
{"text": "RVR One hundred and forty - three patients ( 68 % ) ; 79 with genotype 2 and 64 with genotype 3 had a RVR to treat- ment at week 4 ( Group A ) .", "label": "", "metadata": {}, "score": "64.21563"}
{"text": "For example , HCV - infected African American patients are less re- sponsive to antiviral therapy than the non - Hispanic white population ( 35 , 36 ) .", "label": "", "metadata": {}, "score": "64.370766"}
{"text": "Yoshiyuki Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan J Gastroenterol Hepatol 19:699 - 706 .Interferon - induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection .", "label": "", "metadata": {}, "score": "64.418106"}
{"text": "Fibrosis scores determined on graft biopsy improved in 76 % of treated patients and only 5 % of untreated patients .Improvement did not correlate with SVR ; fibrosis scores improved in 65 % of treated patients who did not achieve SVR ( 74 ) .", "label": "", "metadata": {}, "score": "64.437454"}
{"text": "Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine .Mariko Kobayashi Research Institute for Hepatology , Toranomon Hospital , Tokyo , Japan J Med Virol 79:1472 - 7 .", "label": "", "metadata": {}, "score": "64.48796"}
{"text": "Factors associated with the virological response of lamivudine - resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine .Tetsuya Hosaka Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Tokyo 105 8470 , Japan J Gastroenterol 42:368 - 74 .", "label": "", "metadata": {}, "score": "64.50334"}
{"text": "Introduction .Chronic viral hepatitis C is one of the most serious chronic infections affecting 170 million people worldwide .In Europe more than 9 million people are infected with this virus [ 1 ] .", "label": "", "metadata": {}, "score": "64.70815"}
{"text": "Among patients receiving CIFN 15mg / day , end - of - treatment responses were noted in 28 , 19 and 6 % of patients respectively .", "label": "", "metadata": {}, "score": "64.7408"}
{"text": "Loguercio C , Di PM , Di Marino MP , et al .Drinking habits of subjects with hepatitis C virus - related chronic liver disease : prevalence and effect on clinical , virological and pathological aspects .", "label": "", "metadata": {}, "score": "64.758675"}
{"text": "Cytokines have a role in the mechanisms of host defense against infectious agents .They induce inflammatory responses that can lead to tissue injury and serve as antiviral effectors as well .", "label": "", "metadata": {}, "score": "65.01287"}
{"text": "Lo Re V III , Kostman JR .Management of chronic hepatitis C. Postgrad Med J 2005 ; 81 : 376 - 82 .Liang TJ , Rehermann B , Seeff LB , Hoofnagle JH . Pathogen-", "label": "", "metadata": {}, "score": "65.10826"}
{"text": "While many of these drugs seem to hold promise as either a primary or an adjunctive treatment for patients with chronic hepati- tis C , they are years from market and their safety and efficacy are uncertain in difficult - to - treat patients ( 122 ) .", "label": "", "metadata": {}, "score": "65.15076"}
{"text": "N Engl J Med 1995 ; 332 : 1457 - 62 .Shiffman ML .Management of patients with chronic hepa- titis C virus infection and previous nonresponse .", "label": "", "metadata": {}, "score": "65.17241"}
{"text": "All patients were divided into 3 subgroups : CC , CT / TC , and TT .Different patient factors , laboratory tests , viral kinetics , and treatment response were analyzed .", "label": "", "metadata": {}, "score": "65.27759"}
{"text": "Page 11 .Everson GT .Treatment of chronic hepatitis C in patients with decompensated cirrhosis .Rev Gastroenterol Disord 2004 ; 4(Suppl . 1 ) : S31 - 8 .", "label": "", "metadata": {}, "score": "65.28967"}
{"text": "Sustained Virological Response 12 Weeks Post Treatment ( SVR12 ) [ Time Frame : 12 weeks post treatment , up to 60 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "65.312744"}
{"text": "Here , we determined the predictive factors of sustained virological response ( SVR ) and early virologic response ( EVR ) to this treatment ... .", "label": "", "metadata": {}, "score": "65.348434"}
{"text": "DISCUSSION : Tumours inside the Milan criteria have a better survival .The majority of the patients have an underlying cirrhosis as background for the development of a HCC .", "label": "", "metadata": {}, "score": "65.49491"}
{"text": ": SPRINT-1 investigators .Efficacy of boceprevir , an NS3 protease inhibitor , in combination with peginterferon alfa-2b and ribavirin in treatment - naive patients with genotype 1hepatitis C infection ( SPRINT-1 ) : an open - label , randomised , multicentre phase 2 trial .", "label": "", "metadata": {}, "score": "65.53019"}
{"text": "Kiminori Uka Department of Gastroenterology , Toranomon Hospital , Minato ku , Tokyo , Japan J Gastroenterol 41:470 - 5 .The aim of this study was to analyze the response to interferon ( IFN ) monotherapy in young HCV patients ... .", "label": "", "metadata": {}, "score": "65.8117"}
{"text": "The exclusion criteria included co - infection with human immunodeficiency virus ( HIV ) or hepatitis B virus ( HBV ) , alcohol intake averaging greater than 20 g per day , active drug abuse , chronic systemic disease , psychiatric disorders , autoimmune disease , pregnancy or lactation .", "label": "", "metadata": {}, "score": "65.82112"}
{"text": "Tetsuya Hosaka Department of Hepatology , Toranomon Hospital , Tokyo , Japan Liver Int 30:1461 - 70 .Efficacy of switching to entecavir monotherapy in Japanese lamivudine - pretreated patients .", "label": "", "metadata": {}, "score": "65.85146"}
{"text": "Drug : BI 201335 .BI 201335 once a day ( QD ) for 24 weeks .Drug : Pegylated Interferon - alpha ( IFN ) .", "label": "", "metadata": {}, "score": "65.916115"}
{"text": "Clinical features of hepatitis B virus genotype A in Japanese patients .Mariko Kobayashi Research Institute for Hepatology , Toranomon Hospital , 1 3 1 Kajigaya , Takatsu ku , Kawasaki 213 8587 , Japan J Gastroenterol 38:656 - 62 .", "label": "", "metadata": {}, "score": "65.98755"}
{"text": "PubMed .Zein NN : Clinical significance of hepatitis C virus genotypes .ClinMicrobiol Rev 2000 , 13 : 223 - 235 .Nevens E , Van Vlierberghe H , D'Heygere E , et al .", "label": "", "metadata": {}, "score": "66.05182"}
{"text": "wPercentage of patients with actual non - sustained virological response of those who were predicted to have non - sustained virological response ( i.e. HCV RNA positive at 6 months post - therapy ) .", "label": "", "metadata": {}, "score": "66.19771"}
{"text": "Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine - resistant mutants of hepatitis B virus .Tetsuya Hosaka Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Intervirology 47:362 - 9 .", "label": "", "metadata": {}, "score": "66.229126"}
{"text": "The National Center for Health Statistics recently estimated that 1.3 % of the US population - or 3.2 million people - have chronic HCV infection ( 3 ) .", "label": "", "metadata": {}, "score": "66.24486"}
{"text": "Nguyen HA , Miller AI , Dieperink E , et al .Spectrum of disease in U.S. veteran patients with hepatitis C. Am J Gastroenterol 2002 ; 97 : 1813 - 20 .", "label": "", "metadata": {}, "score": "66.40897"}
{"text": "IL-28B gene polymorphism currently seems to be one of the strongest predictors of SVR [ 7 ] .The aim of this study was to detect IL-28B gene polymorphism in chronic hepatitis C patients in Latvia and to analyze therapy results in patients with different IL-28B gene polymorphisms .", "label": "", "metadata": {}, "score": "66.46444"}
{"text": "3 ) ( 131 ) .In this analysis , 80 % of sustained responders , including treatment - na\u0131 \u00a8ve and retreatment patients , had unde- tectable levels of virus by week 8 .", "label": "", "metadata": {}, "score": "66.49656"}
{"text": "Although genotype 1a present a lower age and lower baseline HCVRNA level respect to genotype 1b patients , the logistic regression analysis and in particular Adjusted odds ratio shows the independent influence of genotype 1a on SVR without the disturbing influence of other variables .", "label": "", "metadata": {}, "score": "66.51997"}
{"text": "Only two patients ( 7 % ) discontinued therapy because of adverse effects , and eight patients ( 30 % ) in the intent - to - treat population achieved an SVR .", "label": "", "metadata": {}, "score": "66.53558"}
{"text": "Walsh MJ , Jonsson JR , Richardson MM , et al .Non - response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 ( SOCS-3 ) in patients with chronic hepatitis C , viral geno- type 1 .", "label": "", "metadata": {}, "score": "66.709045"}
{"text": "Due to a rise in HCV induced liver cirrhosis , hepatocellular carcinoma becomes more prevalent in Western European countries .INTRODUCTION :Due to a rise in HCV induced liver cirrhosis , hepatocellular carcinoma becomes more prevalent in Western European countries .", "label": "", "metadata": {}, "score": "66.78595"}
{"text": "Tomokazu Kawaoka Department of Hepatology , Toranomon Hospital , 2 2 2 Toranomon , Tokyo 105 8470 , Japan J Gastroenterol 42:395 - 401 .The aim of this study was to evaluate the efficacy of lamivudine therapy in elderly patients with chronic HBV infection ... .", "label": "", "metadata": {}, "score": "66.794266"}
{"text": "A closed cohort study including matched control patients .Kenji Ikeda Department of Gastroenterology , Toranomon Hospital , and Okinaka Memorial Institute for Medical Research , Tokyo , Japan Oncology 65:204 - 10 .", "label": "", "metadata": {}, "score": "66.91869"}
{"text": "Hematological biochemical testing in participants were performed , on an outpatient basis , at weeks 4 , 8 , 12 , 16 and 24 during treatment , and 24 weeks after the end of treatment .", "label": "", "metadata": {}, "score": "66.94372"}
{"text": "PubMed View Article .Dienstag JL , McHutchinson J : American Gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006 , 130 : 231 - 264 .", "label": "", "metadata": {}, "score": "66.98314"}
{"text": "Akihito Tsubota Department of Gastroenterology , Toranomon Hospital , Minato ku , Tokyo , Japan J Med Virol 75:27 - 34 .The results suggest that early monitoring of viral kinetics is a useful measure to predict virological response , and might facilitate development of rational and effective therapeutic strategies ... .", "label": "", "metadata": {}, "score": "67.03428"}
{"text": "The number of participants with aspartate aminotransferase ( AST ) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment .", "label": "", "metadata": {}, "score": "67.03444"}
{"text": "In the present study , we examined the clinical features associated with HBV genotype A disease in the Tokyo metropolitan area ... .Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus .", "label": "", "metadata": {}, "score": "67.08039"}
{"text": "Hepatology 2008 , 47:1837 - 1845 .BMC Gastroenterology 2010 10:21 .Mecenate et al .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .", "label": "", "metadata": {}, "score": "67.090096"}
{"text": "View Article .Rizzetto M , Colombo M , Ascione A , et al .: Effectiveness of hepatitis C virus treatment in real life practice : a prospective observational multicenter study in Italy ( PROBE ) .", "label": "", "metadata": {}, "score": "67.112595"}
{"text": "Conclusions : This trial confirms the value of using peginter - feron alfa-2a in both na\u00efve and relapsed patients and provides support for a more tailored approach to treatment for relapsers and particulary for patients with a slow viral response .", "label": "", "metadata": {}, "score": "67.151276"}
{"text": "Conclusions : This trial confirms the value of using peginter - feron alfa-2a in both na\u00efve and relapsed patients and provides support for a more tailored approach to treatment for relapsers and particulary for patients with a slow viral response .", "label": "", "metadata": {}, "score": "67.151276"}
{"text": "Introduction : Nationwide studies are mandatory to assess changes in the epidemiology of HBV infection in Europe .Introduction : Nationwide studies are mandatory to assess changes in the epidemiology of HBV infection in Europe .", "label": "", "metadata": {}, "score": "67.371"}
{"text": "Norio Akuta Division of Gastroenterology , Toranomon Hospital , Tokyo , Japan Dig Dis Sci 48:1654 - 7 .Long - term follow - up of HBeAg - positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B .", "label": "", "metadata": {}, "score": "67.46707"}
{"text": "Overweight and obesity , hepatic steatosis , and progression of chronic hepa- titis C : a retrospective study on a large cohort of patients in the United States .", "label": "", "metadata": {}, "score": "67.549164"}
{"text": "data [ 7 ] , published in 2010 , IL-28B gene polymorphism between Caucasians is distributed as follows : CC 37 % , CT 51 % , and TT 12 % .", "label": "", "metadata": {}, "score": "67.70368"}
{"text": "The number of participants with aspartate aminotransferase ( AST ) in normal range at the end of treatment when patients do not have sustained virological response 12 weeks post treatment .", "label": "", "metadata": {}, "score": "67.71161"}
{"text": "Norio Akuta Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Intervirology 48:372 - 80 .Non - virological responders ( NVRs , namely ultimate resistant cases ) who do not achieve HCV - RNA negativity during treatment are also encountered .", "label": "", "metadata": {}, "score": "67.74728"}
{"text": "Retreatment with peg - IFN has been successful in some patients who exhibit an inadequate response to conventional IFN treatment , particularly those who have relapsed .", "label": "", "metadata": {}, "score": "67.79051"}
{"text": "Long - term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B .Yasuji Arase Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Am J Med 119:71 .", "label": "", "metadata": {}, "score": "67.89642"}
{"text": "Mariko Kobayashi Research Institute for Hepatology , Toranomon Hospital , Kawasaki , Japan J Gastroenterol 37:35 - 9 .Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection .", "label": "", "metadata": {}, "score": "67.93509"}
{"text": "di Belgiojoso GB , Ferrario F , Landriani N. Virus - related glomerular diseases : histological and clinical aspects .J Nephrol 2002 ; 15 : 469 - 79 .", "label": "", "metadata": {}, "score": "68.01308"}
{"text": "Centers for Disease Control and Prevention .Disease burden from viral hepatitis A , B , and C in the United States .Updated : 2004 .", "label": "", "metadata": {}, "score": "68.21836"}
{"text": "No patient of Group A1 withdrew from the study because of adverse effects .Adverse events related to treatment in the 3 study groups are reported in the Table 5 .", "label": "", "metadata": {}, "score": "68.26825"}
{"text": "Eighteen subtype 1a ( 11 % ) and 16 subtype 1b ( 7 % ) patients stopped antiviral treatment due to adverse effects .Six patients stopped during the first month of treatment and the remaining patients during the following months .", "label": "", "metadata": {}, "score": "68.321205"}
{"text": "Management of Chronic hepatitis C ' 2005 ; 81 : 378 ; with permission from BMJ Publishing Group Ltd ( 4 ) . ]Liver International ( 2007 ) 1298 c ?", "label": "", "metadata": {}, "score": "68.359375"}
{"text": "Sulkowski MS .Treatment algorithm for the management of hepatitis C in HIV - coinfected persons .J Hepatol 2006 ; 44(Suppl . 1 ) : S49 - 55 .", "label": "", "metadata": {}, "score": "68.41343"}
{"text": "Norio Akuta Division of Gastroenterology , Toranomon Hospital , Tokyo , Japan Dig Dis Sci 47:405 - 14 .We conclude that CSWT alone is a very short - term treatment of just three weeks that may be more effective for long - term clinical remission than CSWT followed by IFN - alpha in Japanese genotype C - dominant hepatitis B patients ... .", "label": "", "metadata": {}, "score": "68.79843"}
{"text": "Armstrong GL , Wasley A , Simard EP , Mcquillan GM , Kuhnert WL , Alter MJ .The prevalence of hepatitis C virus infection in the United States , 1999 through 2002 .", "label": "", "metadata": {}, "score": "68.8312"}
{"text": "Recent evidence .Minerva Urol Nefrol 2004 ; 56 : 249 - 57 .Salama G , Rostaing L , Sandres K , Izopet J. Hepatitis C virus infection in French hemodialysis units : a multicenter study .", "label": "", "metadata": {}, "score": "68.928604"}
{"text": "RBV dose was weight based : 1000mg / day for o75 kg or 1200mg / day for 475 kg .The SVR rate was 30 % ( 23/ with40%ofthe IFN - a-2b group Table 2 . 1 % ) Severe bone marrow depression Seizures Tinnitus and hearing loss Hyperglycaemia Renal failure Pneumonitis Ribavirin Common ( Z10 % ) Haemolytic anaemia ( dose dependent )", "label": "", "metadata": {}, "score": "68.940674"}
{"text": "HCVRNA level was expressed as log 10 IU / ml .HCVRNA was measured before the treatment , at weeks 4,12,24,48 of treatment and 24 weeks after the final treatment .", "label": "", "metadata": {}, "score": "68.97547"}
{"text": "2007 Blackwell Munksgaard 1299 Kemmer and Neff Difficult - to - treat HCV patients .Page 4 .Thus , advanced age alone reduces antiviral effectiveness , but the addition of viral and hepatic risk factors further worsens response .", "label": "", "metadata": {}, "score": "69.00314"}
{"text": "Comparison of long - term prognosis in patients with chronic hepatitis B treated with lamivudine , with or without severe acute exacerbation ( SAE ) ... .", "label": "", "metadata": {}, "score": "69.04503"}
{"text": "In patients with genotype 1 , SVR was achieved in 16 patients ( 84 % ) in CC subgroup versus 30 patients ( 47.6 % ) in non - CC subgroups , .", "label": "", "metadata": {}, "score": "69.04652"}
{"text": "Significance was defined at a .Study was approved by the Independent Ethics Committee for clinical investigation of drugs and pharmaceutical products in Latvia .Study was performed during the 2009 - 2011 at the State Agency \" Infectology center of Latvia . \"", "label": "", "metadata": {}, "score": "69.10882"}
{"text": "Infection with the hepatitis C virus ( HCV ) represents an important public health problem and is a leading cause of chronic hepatitis , cirrhosis and hepatocellular carcinoma .", "label": "", "metadata": {}, "score": "69.12989"}
{"text": "J. Med .Virol .( c ) 2010 Wiley - Liss , Inc ..Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus - related cirrhosis .", "label": "", "metadata": {}, "score": "69.22168"}
{"text": "Of the 137 patients , 112 ( 82 % ) achieved SVR .Of 87 patients with IL28B single nucleotide polymorphism ( SNP ) rs8099917 genotype TT , 84 ( 97 % ) achieved SVR .", "label": "", "metadata": {}, "score": "69.29554"}
{"text": "Cox proportional hazards model showed a significant association between MELD score and the probability of organ allocation .Conclusion : Laboratory - dependent significant differences in MELD score were observed between the six transplant centers .", "label": "", "metadata": {}, "score": "69.31929"}
{"text": "Glue P , Fang JW , the Hepatitis C Intervention Therapy Group , et al .Pegylated interferon - alpha2b : pharmacoki- netics , pharmacodynamics , safety , and preliminary efficacy data .", "label": "", "metadata": {}, "score": "69.327675"}
{"text": "However , the success of antiviral therapy diminishes in the face of decom- pensated cirrhotic disease owing to the severity of adverse effects in these severely ill patients ( 29 , 32 ) .", "label": "", "metadata": {}, "score": "69.436844"}
{"text": "Journal compilation c ?2007 Blackwell Munksgaard Difficult - to - treat HCV patients Kemmer and Neff .Page 3 . baseline viral loads were o5.55log10copies / mL. Dur- ing the first 24h of IFN - a-2b therapy , reductions in viraemia were greater in patients with low viral loads vs. those with baseline loads Z5.55log10copies / mL ( 1.26 ? 0.14 vs. 0.70 ?", "label": "", "metadata": {}, "score": "69.45508"}
{"text": "At listing there were no significant differences between the MILIN and MILDOWN group for age , gender and underlying liver disease .Median time on waiting list between the two groups was similar ( 120 days vs. 115.5 days ) .", "label": "", "metadata": {}, "score": "69.54067"}
{"text": "Hepatitis B virus - related hepatocellular carcinogenesis and its prevention .Kenji Ikeda Department of Gastroenterology , Toranomon Hospital , Tokyo , and Okinaka Memorial Institute for Medical Research , Tokyo , Japan Intervirology 48:29 - 38 .", "label": "", "metadata": {}, "score": "69.60554"}
{"text": "Kalia H , Lopez PM , Martin P. Treatment of HCV in patients with renal failure .Arch Med Res 2007 ; 38 : 628 - 33 .", "label": "", "metadata": {}, "score": "69.785965"}
{"text": "Anaemia was the most frequent cause of dose reduction .Total discontinuation , dose modifications and adverse events related to treatment are showed in Table 4 .", "label": "", "metadata": {}, "score": "69.79683"}
{"text": "The body mass index inversely correlates with SVR ( 46 ) , and serum leptin , which is elevated in obese patients , is a predictor of antiviral treatment resistance in HCV infection with low viraemia ( 47 ) .", "label": "", "metadata": {}, "score": "69.91822"}
{"text": "Long - term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance .Yasuji Arase Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Intervirology 50:161 - 5 .", "label": "", "metadata": {}, "score": "69.955536"}
{"text": "A cut - off value of 7.4 ng / ml \u03b1 - fetoprotein was determined for non - sustained virological response ; sensitivity , specificity , PPV , NPV , and accuracy were 63.6 % , 87.5 % , 77.8 % , 77.8 % , and 77.8 % , respectively .", "label": "", "metadata": {}, "score": "69.97728"}
{"text": "Yoshiyuki Suzuki Department of Hepatology , Toranomon Hospital , Tokyo , Japan J Hepatol 58:655 - 62 .Improved therapeutic options for chronic hepatitis C virus ( HCV ) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response ... .", "label": "", "metadata": {}, "score": "70.39014"}
{"text": "Drug : Ribavirin ( RBV ) .Ribavirin ( RBV ) for 24 or 48 weeks .Drug : Placebo .Placebo to BI201335 for 24 weeks .", "label": "", "metadata": {}, "score": "70.402"}
{"text": "In Belgium , successful downstaging of HCC is an accepted non - standard- ized exception ( NSE ) for liver allocation .This NSE group rep- resents a unique cohort to analyse if OLT can be safely offered to patients with those extended allocation criteria .", "label": "", "metadata": {}, "score": "70.58523"}
{"text": "[ Designated as safety issue : No ] .Current Secondary Outcome Measures ICMJE ( submitted : September 22 , 2015 ) .Virological Response After 24 Weeks of Treatment Discontinuation ( SVR24 ) [ Time Frame : 24 weeks post treatment , up to 72 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "70.65199"}
{"text": "In total , 134 patients attained early virological response ( EVR ) ; 88 ( 65.7 % ) of those patients attained SVR .In contrast , 82 ( 96.5 % ) of the 85 patients who did not attain EVR also did not attain SVR .", "label": "", "metadata": {}, "score": "70.85095"}
{"text": "Mariko Kobayashi Research Institute for Hepatology , Toranomon Hospital , Tokyo , Japan Intervirology 46:157 - 63 .Factors influencing the resolution of persistent hepatitis B virus ( HBV ) infection were sought for ... .", "label": "", "metadata": {}, "score": "70.91112"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Specific antibodies against poly(ethylene glycol ) ( anti - PEG ) were induced in animals following exposure to PEG - conjugated proteins and particles , resulting in rapid clearance of PEG - conjugated agents .", "label": "", "metadata": {}, "score": "71.18947"}
{"text": "Full - text .Evidence suggests that a similar response rate may be obtained with shorter treatment periods , especially in patients with a rapid virological response ( RVR ) .", "label": "", "metadata": {}, "score": "71.29233"}
{"text": "The aim of this paper was to detect IL-28B gene polymorphism in Latvia and to analyze therapy results .This is the first study on IL-28B gene polymorphism in Latvia .", "label": "", "metadata": {}, "score": "71.57823"}
{"text": "Percentage of sustained responders who showed first viral response by week .[ Reprinted with permission of John Wiley & Sons Inc. , Hepatology , 1998 ; 28 , 1411 - 1415 .", "label": "", "metadata": {}, "score": "71.68084"}
{"text": "142 patients were treated with the standard of care treatment .Results were analyzed according to IL-28B polymorphism .Results .There were 53 patients ( 33 % ) with CC genotype , 84 patients ( 53 % ) with CT / TC genotype , and 22 patients ( 14 % ) with TT genotype .", "label": "", "metadata": {}, "score": "71.785194"}
{"text": "Results : Overall 381 patients were listed in Belgium during the study period .Of these , 320 received OLT .248 were MILIN , 62 were MIL- DOWN and 10 were transplanted outside MC .", "label": "", "metadata": {}, "score": "71.819984"}
{"text": "Schneeberger PM , Keur I , van Loon AM , et al .The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands : a nationwide prospective study .", "label": "", "metadata": {}, "score": "71.95831"}
{"text": "Kenji Ikeda Department of Hepatology , Toranomon Hospital , Tokyo , Japan Am J Med 119:977 - 85 .To elucidate the incidence of hepatitis activation and hepatocellular carcinogenesis in patients with negative HBe antigen and normal aminotransferase , long - term observation was performed in a retrospective cohort ... .", "label": "", "metadata": {}, "score": "72.08231"}
{"text": "Yasuji Arase Department of Hepatology , Toranomon Hospital , Toranomon , Minato ku , Tokyo , Japan J Med Virol 79:1485 - 90 .The relative risk of HCC development in patients with BR was 0.36 compared with patients without BR .", "label": "", "metadata": {}, "score": "72.246"}
{"text": "Results : During therapy 93.1 % of the patients lose weight .In according to fat stores all male patients were eutrophics whereas 25 % of female showed signs of malnutrition .", "label": "", "metadata": {}, "score": "72.24979"}
{"text": "Cross - tabulation of RVR vs .SVR showed that the positive predictive value ( PPV ) of RVR for the achievement of SVR was 82.0 % for subtype 1a and 77.4 % for subtype 1b ( data not shown ) .", "label": "", "metadata": {}, "score": "72.30144"}
{"text": "9286 , pp .958 - 965 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. J. Hadziyannis , H. Sette , T. R. Morgan et al . , \" Peginterferon-", "label": "", "metadata": {}, "score": "72.336105"}
{"text": "The number of participants with alanine aminotransferase ( ALT ) in normal range post treatment when patients do not have sustained virological response 12 weeks post treatment .", "label": "", "metadata": {}, "score": "72.66735"}
{"text": "While the most prevalent genotype of IL-28B in Latvia is CT , the most favorable response to treatment and SVR is seen in genotype CC patients .", "label": "", "metadata": {}, "score": "72.73889"}
{"text": "Severe neutro- paenia and the corresponding increased risk of infection and haemolytic anaemia are primary treat- ment - limiting toxicities associated with IFN plus RBV ( 61 , 71 ) .", "label": "", "metadata": {}, "score": "72.77281"}
{"text": "Am J Transplant 2001 ; 1 : 171 - 8 .Gallay BJ , Alpers CE , Davis CL , Schultz MF , Johnson RJ .", "label": "", "metadata": {}, "score": "72.93597"}
{"text": "Virol .\u00a9 2013 Wiley Periodicals , Inc. .[ Show abstract ] [ Hide abstract ] ABSTRACT : Abnormal serum lipid profiles have been noted in patients with chronic hepatitis C virus ( HCV ) infection .", "label": "", "metadata": {}, "score": "73.118484"}
{"text": "Surprisingly , the SVR rate was 28 % with the 18/9mg / day induction regimen but 32 % with the 9mg / day regimen .", "label": "", "metadata": {}, "score": "73.24317"}
{"text": "Franceschi S , Montella M , Polesel J , et al .Hepatitis viruses , alcohol , and tobacco in the etiology of hepatocellular carcinoma in Italy .", "label": "", "metadata": {}, "score": "73.83876"}
{"text": "Department of Digestive and Liver Disease , Azienda Ospedaliera Sant'Andrea .Medicine of Migration National Institute for Migrant Health and Poverty .Department of Internal Medicine and liver unit , Ospedale Generale di Marino .", "label": "", "metadata": {}, "score": "73.88624"}
{"text": "To evaluate the long - term effects of corticosteroid withdrawal therapy ( CSWT ) in young adult Japanese patients with chronic hepatitis B ( CH - B ) virus infection ... .", "label": "", "metadata": {}, "score": "73.907776"}
{"text": "Norio Akuta Department of Hepatology , Toranomon Hospital , and Okinaka Memorial Institute for Medical Research , Tokyo , Japan Hepatology 56:2134 - 41 .In patients of Arg70 at the initial visit , the cumulative change rates from Arg70 to Gln70(His70 ) in IL28B rs8099917 non - TT genotype were significantly higher than those in the TT genotype ... .", "label": "", "metadata": {}, "score": "73.9436"}
{"text": "Sixty - seven patients ( 32 % ) did not achieve a RVR at week 4 and continued with combination ther- apy for 24 weeks ( Group B ) .", "label": "", "metadata": {}, "score": "73.999756"}
{"text": "Virological features of HBV - HCV dual infection .Norio Akuta Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Dig Dis Sci 49:281 - 8 .", "label": "", "metadata": {}, "score": "74.43153"}
{"text": "2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard 1307 Kemmer and Neff Difficult - to - treat HCV patients .Page 12 .", "label": "", "metadata": {}, "score": "74.454956"}
{"text": "Using the model constructed by these independent variables , positive and negative predictive values and predictive accuracy were 73.3 , 70.1 and 71.9 % respectively .", "label": "", "metadata": {}, "score": "74.508606"}
{"text": "Positive and negative values , clinical sensitivity and specificity of viral load , and log - decline predictors of sustained and non - sustained virological response ?", "label": "", "metadata": {}, "score": "74.71774"}
{"text": "2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard Difficult - to - treat HCV patients Kemmer and Neff .Page 9 . week 1 but increased to nearly 100 % after 12 weeks of treatment ( 25 ) .", "label": "", "metadata": {}, "score": "74.873566"}
{"text": "As the most common blood - borne pathogen in the United States , hepatitis C virus ( HCV ) is an escalating healthcare concern ( 1 ) .", "label": "", "metadata": {}, "score": "74.91358"}
{"text": "80 percent of patients did not miss any dose .We have to stress that chronic viral hepatitis C patients are paying 25 % of treatment costs themselves in Latvia , and 75 % is covered by sick fund .", "label": "", "metadata": {}, "score": "75.043465"}
{"text": "Retreatment of poor responders requires longer durations of therapy , although the optimal duration is not yet determined .Study durations for peg - IFN or CIFN in non - responders and relapsers have ranged from 24 to 72 weeks ( 108 , 110 , 112 , 114 - 117 ) .", "label": "", "metadata": {}, "score": "75.053635"}
{"text": "Responders achieved sustained virological response and were HCV - RNA negative at the end of therapy and 24 weeks after stopping treatment .Nonresponders were HCV - RNA positive at week 12 ( null responders ) , at the end of therapy ( partial responders ) or at week 24 after stopping therapy ( relapsers ) .", "label": "", "metadata": {}, "score": "75.25049"}
{"text": "Par et al .[ 11 ] have published data in CEMED where CC genotype in HCV patients was noted with significantly lower frequency than in healthy controls ( 79/281 , 28.11 % versus 54/104 , 51.92 % ) , suggesting a protective role of this variant .", "label": "", "metadata": {}, "score": "75.28017"}
{"text": "Highserum leptin is an independent risk factor for non - response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006 ; 12 : 556 - 60 .", "label": "", "metadata": {}, "score": "75.70775"}
{"text": "Fumitaka Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Intervirology 46:182 - 9 .However , the patient cohorts in such studies are relatively small ... .", "label": "", "metadata": {}, "score": "75.85878"}
{"text": "Therefore , stopping therapy at 4 weeks after a negative viral response may help to avoid treatment - related adverse events and allow earlier re - evaluation of retreatment options .", "label": "", "metadata": {}, "score": "76.20111"}
{"text": "2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard 1301 Kemmer and Neff Difficult - to - treat HCV patients .Page 6 .", "label": "", "metadata": {}, "score": "76.253815"}
{"text": "Although the optimal duration of retreatment and the benefits and safety of maintenance therapy have not been determined , an extended duration is likely needed .", "label": "", "metadata": {}, "score": "76.4653"}
{"text": "Although the optimal duration of retreatment and the benefits and safety of maintenance therapy have not been determined , an extended duration is likely needed .", "label": "", "metadata": {}, "score": "76.4653"}
{"text": "in the DITTO study [ 14 ] where the role of genotype appears to be relatively small after early viral clearance .In our study we have observed a slight increase of SVR in patients of Group A1 compared with Group A2 , however , without a difference statistically significant .", "label": "", "metadata": {}, "score": "76.51656"}
{"text": "MATERIALS AND METHODS : Belgian physicians were asked to report all new cases of hepatocellular carcinoma which were seen between January 2003 and December 2003 .", "label": "", "metadata": {}, "score": "76.537186"}
{"text": "[ Time Frame : Week 4 and Week 8 ] [ Designated as safety issue : No ] .The number of participants with alanine aminotransferase ( ALT ) in normal range at the end of treatment ( EoT ) when patients do not have sustained virological response 12 weeks post treatment .", "label": "", "metadata": {}, "score": "76.5434"}
{"text": "All included patients were Caucasians , a majority of them male ( 59 % ) and genotype 1 ( 61 % ) patients .34 patients ( 74 % ) in CC genotype subgroup achieved SVR versus 50 patients ( 52 % ) in non - CC subgroup-41 patient in CT / TC and 9 patients in TT subgroups .", "label": "", "metadata": {}, "score": "76.67836"}
{"text": "In contrast to previous publications , this meta - analysis suggests that HCV-5 response to treatment is closer to HCV-1 than to HCV-2/3 and suggests that in Belgium HCV-5 infection should be treated with the same antiviral regimen as HCV-1 .", "label": "", "metadata": {}, "score": "76.755554"}
{"text": "In contrast to previous publications , this meta - analysis suggests that HCV-5 response to treatment is closer to HCV-1 than to HCV-2/3 and suggests that in Belgium HCV-5 infection should be treated with the same antiviral regimen as HCV-1 .", "label": "", "metadata": {}, "score": "76.755554"}
{"text": "National Institutes of Health Clinical Trials web site , Updated : 2006 .Accessed on 29 October 2007 .Lee WM , Dienstag JL , Lindsay KL , et al .", "label": "", "metadata": {}, "score": "77.07454"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator )", "label": "", "metadata": {}, "score": "77.1189"}
{"text": "Hepatology 2002 ; 36 : 3 - 10 .Potthoff A , Wiegand J , Luth JB , Wedemeyer H , Manns MP , Tillmann HL .", "label": "", "metadata": {}, "score": "77.73897"}
{"text": "Conclusion : In this large Belgian multicentre cohort , overall and recurrence free survival at 1 year are not signifi- cantly different between patients who have been downstaged successfully and patients who were always inside the Milan criteria .", "label": "", "metadata": {}, "score": "77.96376"}
{"text": "Accord- ing to logistic regression analysis , a RVR is an indepen- dent covariate that is predictive of a SVR , along with pretreatment HCV - RNA levels , ALT values and fibrosis scores .", "label": "", "metadata": {}, "score": "77.98937"}
{"text": "There were not statistically significant differences between groups with regard to fibrosis stage and HAI index .Statistical processing of data was done using SPSS v.15.0 and Microsoft Office Excel v.11 .", "label": "", "metadata": {}, "score": "78.05847"}
{"text": "( 72 ) documented an SVR rate of only 12 % and awithdrawal rate attributed to adverse effects of 30 % .Several investigations regarding optimal regimens for transplant recipients were encouraging ( 73 , 74 ) .", "label": "", "metadata": {}, "score": "78.21357"}
{"text": "If we analyze only HCV genotype 1 patients , our data shows slightly better results in comparison with Thompson and Par studies .In CC subgroup SVR was achieved in 69 % ( Thompson ) , 54.34 % ( Par ) , and 84 % in our study .", "label": "", "metadata": {}, "score": "78.652176"}
{"text": "Lancet 2001 ; 358 : 958 - 65 .Mchutchison JG , Gordon SC , for the Hepatitis Interven- tional Therapy Group , et al .", "label": "", "metadata": {}, "score": "78.66974"}
{"text": "Eleven patients ( 13 % ) withdrew because of adverse events , and univariate analysis showed a high- er likelihood of withdrawal owing to adverse events among those age 470 years than those age ? 70", "label": "", "metadata": {}, "score": "78.77441"}
{"text": "Exclusion criteria : .HCV infection of mixed genotype ; Hepatitis B Virus ( HBV ) or Human Immunodeficiency Virus ( HIV ) co - infection .", "label": "", "metadata": {}, "score": "78.88364"}
{"text": "Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B .Akihito Tsubota Department of Gastroenterology , Toranomon Hospital , Minato , Tokyo , Japan J Gastroenterol Hepatol 20:426 - 32 .", "label": "", "metadata": {}, "score": "78.91756"}
{"text": "The duration of the treatment was 48 weeks for genotypes 1 , 4 , 5 and 6 , and 24 weeks for genotypes 2 and 3 .", "label": "", "metadata": {}, "score": "78.98244"}
{"text": "The duration of the treatment was 48 weeks for genotypes 1 , 4 , 5 and 6 , and 24 weeks for genotypes 2 and 3 .", "label": "", "metadata": {}, "score": "78.98244"}
{"text": "Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan .Yoshiyuki Suzuki Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan J Med Virol 76:33 - 9 .", "label": "", "metadata": {}, "score": "79.0916"}
{"text": "Infectious Disease Ospedale di Belcolle strada Sammartinese .Liver Unit Campus Biomedico University .Infectious Disease Ospedale San Camillo de Lellis .Department of Infectious Disease Policlinico Umberto I .", "label": "", "metadata": {}, "score": "79.48137"}
{"text": "Kenji Ikeda Department of Gastroenterology , Toranomon Hospital , Tokyo , Japan Dig Dis Sci 51:603 - 9 .Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C .", "label": "", "metadata": {}, "score": "79.74556"}
{"text": "T12PR48 improvesthe SVR rate in null responders , patients with the non - TT genotype , and null responderswith a non - TT genotype .[ Show abstract ] [ Hide abstract ] ABSTRACT : Even when treated with telaprevir - based triple therapy , some patients fail to achieve a sustained virological response .", "label": "", "metadata": {}, "score": "79.837875"}
{"text": "Infection with hepatitis B virus genotype A in Tokyo , Japan during 1976 through 2001 .Mariko Kobayashi Research Institute for Hepatology , Toranomon Hospital , 1 3 1 Kajigaya , Takatsu ku , 213 8587 Kawasaki , Japan J Gastroenterol 39:844 - 50 .", "label": "", "metadata": {}, "score": "80.0047"}
{"text": "United States , Austria , Belgium , Canada , France , Germany , Japan , Portugal , Puerto Rico , Spain , Switzerland , United Kingdom Patients with chronic hepatitis C virus ( HCV ) infection and disease - related complications - among them cirrhosis and liver failure - pose a particular management challenge .", "label": "", "metadata": {}, "score": "80.14357"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "80.18895"}
{"text": "Prediction formulae were constructed by significantly independent factors .Using the model constructed by these factors , positive and negative predictive values and predictive accuracy were 79.8 % , 88.8 % and 86.2 % , respectively .", "label": "", "metadata": {}, "score": "80.205154"}
{"text": "zPercentage of patients correctly predicted to have a sustained virological response of all patients having sustained virological response .kNone of the log decline rules at week 4 attained a negative predictive value of 495 % .", "label": "", "metadata": {}, "score": "80.20565"}
{"text": "The adjusted O.R. were calculated by multiple logistic regression analysis in order to identify independent predictors of SVR .Adjustment were made for all of the variables considered at univariate analyses .", "label": "", "metadata": {}, "score": "80.67125"}
{"text": "Ethics The study was approved by a central ethic committee ( S. Camillo Hospital , Rome , Italy ) and was conducted according to the guidelines of the International Confer- ence on Harmonization for Good Clinical Practice .", "label": "", "metadata": {}, "score": "80.88878"}
{"text": "Initial enrollment plans included 210 patients .Intention to treat analysis was performed .All data were expressed as the median and range for discrete variables and as counts and percentage for qualitative variables .", "label": "", "metadata": {}, "score": "81.19443"}
{"text": "Symptoms are milder and more likely to disappear in lymphocytic colitis .Ticlopidine and flutamide should be added to the list of drugs inducing colitis .", "label": "", "metadata": {}, "score": "81.39194"}
{"text": "Author details 1Liver Unit Villa Betania Hospital , Rome , Italy.2Liver Unit San Camillo Forlanini Hospital , Rome , Italy.3Liver Unit Pertini Hospital , Rome , Italy .", "label": "", "metadata": {}, "score": "81.50262"}
{"text": "Atlanta , GA : US Dept of Health and Human Services , Centers for Disease Control and Prevention ; 2005 .Management of hepatitis C : 2002 .", "label": "", "metadata": {}, "score": "81.659485"}
{"text": "Adapted from CMAJ ; 174 : 649 - 659 by permission from the publisher .r Canadian Medical Association ( 107 ) .Table 3 . 15/19 ( 79 % ) 21/44 ( 48 % ) 10/20 ( 50 % ) 16/45 ( 36 % ) 0.059 0.24 [ Adapted with permission of Springer Heidelberg from Digestive Diseases & Sciences ; 50 : 227 - 232 .", "label": "", "metadata": {}, "score": "81.831894"}
{"text": "Statistical analysis .All analysis were performed on the basis of the intention to treat ( ITT);i.e . , the denominator included all subjects who received at least 1 dose of treatment .", "label": "", "metadata": {}, "score": "81.912025"}
{"text": "Results Enrollment in the CLEO Centers started in July 2006 , and the trial ended in January 2008 .Two hundred and ten outpatients were consecutively enrolled .", "label": "", "metadata": {}, "score": "82.33513"}
{"text": "Similarly , psychia- tric disorders ( e.g. depression ) present before treat- ment initiation or resulting from treatment may compromise compliance and cause early treatment discontinuation ( 8 , 26 ) .", "label": "", "metadata": {}, "score": "82.5114"}
{"text": "2007 The Authors .Journal compilation c ?2007 Blackwell Munksgaard Difficult - to - treat HCV patients Kemmer and Neff .Data provided are for informational purposes only .", "label": "", "metadata": {}, "score": "83.11039"}
{"text": "Consensus IFN , another option for the retreatment of chronic HCV infection , is associated with SVR rates of 26 - 30 % in non - responders and rates as high as 58 % in relapsers ( 110 - 112 ) .", "label": "", "metadata": {}, "score": "83.29112"}
{"text": "Labome .Org \u00a9 2015 All Rights Researved Princeton , New Jersey 08540 , USA Purpose : Successful downstaging of hepatocellular carcinoma ( HCC ) into the Milan criteria ( MC ) remains a controversial indication for orthotopic liver transplantation ( OLT ) .", "label": "", "metadata": {}, "score": "83.635956"}
{"text": "Marie Matsuda Research Institute for Hepatology , Toranomon Branch Hospital , 1 3 1 Kajigaya , Takatsu ku , Kawasaki 213 8587 , Japan J Gastroenterol 39:34 - 40 .", "label": "", "metadata": {}, "score": "84.07617"}
{"text": "Recent guidelines on management of HBV patients were generally followed , but systematic HBV DNA measurements and HDV coinfection screening should be reinforced .Conclusion : In Belgium , an inactive carrier state was a common form of chronic HBV infection .", "label": "", "metadata": {}, "score": "84.35486"}
{"text": "Both .Ages .18 Years to 70 Years .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects .", "label": "", "metadata": {}, "score": "84.39122"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Background : More than 3 % of the world population is chronically infected with hepatitis C virus .", "label": "", "metadata": {}, "score": "84.77554"}
{"text": "All Data were expressed as the median and range for discrete variables and as counts and percentages for qualitative variables .The differences between the groups were compared using non parametric tests ( the Mann Whitney U test for continuous variables and \u03c7 2 test for parametric variables ) .", "label": "", "metadata": {}, "score": "85.33684"}
{"text": "In the patients having genotype non - TT , those of Arg70 gained high sustained virological response ( 50 % ) , and sustained virological response ( 12 % ) was the worst in patients who possessed both genotype non - TT and Gln70(His70 ) ... .", "label": "", "metadata": {}, "score": "85.859215"}
{"text": "Charlton MR , Pockros PJ , Harrison SA .Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006 ; 43 : 1177 - 86 .", "label": "", "metadata": {}, "score": "85.90585"}
{"text": "Exclusion Criteria : .Non compensated thyroid dysfunction .Recent history of epilepsy ( less than 6 months ) .Absolute contraindications to one of the drug of combination therapy .", "label": "", "metadata": {}, "score": "86.77112"}
{"text": "The most common genotype of IL28B in Latvia is CT / TC , with an incidence of 53 % .Patients with CC genotype achieved SVR more often than CT or TT subgroups .", "label": "", "metadata": {}, "score": "87.25398"}
{"text": "Regardless , the number of Re - use of this article is permitted in accordance with the Creative Common Deed , Attibution 2.5 , which does not permit commercial exploitation .", "label": "", "metadata": {}, "score": "87.970276"}
{"text": "Table 4 Factors independently associated with sustained virological response according to stepwise logistic regression analysis .Mecenate et al .Page 6 .12Division of Infectious disease Policlinico Umberto I Rome , Italy .", "label": "", "metadata": {}, "score": "88.41146"}
{"text": "Norio Akuta Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 0001 , Japan J Med Virol 75:491 - 8 .", "label": "", "metadata": {}, "score": "88.50722"}
{"text": "Full - text .Some of these patients may fail to respond to current therapy ( non - responders ) , and some are affected so severely that treatment puts them at an unacceptable risk for complications .", "label": "", "metadata": {}, "score": "88.629906"}
{"text": "Norio Akuta Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 0001 , Japan J Med Virol 75:550 - 8 .", "label": "", "metadata": {}, "score": "88.72652"}
{"text": "Categorical data were analysed using the chi - square test with the Yates 's correction and the Fisher 's exact test .The relationship between pretreatment independent covariates and the rate of SVR was examined by step- wise logistic regression analysis with related odds ratio and 95 % confidence intervals ( 95 % CI ) .", "label": "", "metadata": {}, "score": "89.116165"}
{"text": "Takashi Someya Department of Hepatology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 8470 , Japan J Gastroenterol 41:1206 - 13 .", "label": "", "metadata": {}, "score": "90.18637"}
{"text": "Publisher conditions are provided by RoMEO .Differing provisions from the publisher 's actual policy or licence agreement may be applicable .\" While supporting 24 weeks as the overall standard of care , Manns et al .", "label": "", "metadata": {}, "score": "90.83182"}
{"text": "Table 3 .Factors associated with the likelihood of SVR .Crude and adjusted Odds Ratios ( O.R. ) derived by multiple logistic regression analysis .", "label": "", "metadata": {}, "score": "91.14636"}
{"text": "Ann Intern Med 2004 ; 140 : 346 - 55 .Crippin JS , McCashland T , Terrault N , Sheiner P , Charlton MR .", "label": "", "metadata": {}, "score": "91.38078"}
{"text": "Authors ' contributions .AMP Concept - Design - Manuscript editing - Manuscript review - Manuscript preparation , Data acquisition MR Concept - Design - Literature search manuscript review , manuscript preparation , TS Statistical analysis , manuscript editing , manuscript review .", "label": "", "metadata": {}, "score": "92.057846"}
{"text": "Norio Akuta Department of Hepatology , Toranomon Hospital , Tokyo , Japan Hepatology 46:1357 - 64 . .5times the upper limit of normal ( 25.7 % ) compared with the others ( 2.4 % ) ... .", "label": "", "metadata": {}, "score": "92.25717"}
{"text": "These results are similar to our data : CC33 % , CT 53 % , and TT 14 % .SVR rates achieved in Thompson 's study are 69 % of patients in CC group , 33 % in CT group , and 27 % in TT group [ 7 ] .", "label": "", "metadata": {}, "score": "92.285194"}
{"text": "Lancet 2001 , 358:958 - 965 .Ann Intern Med 2004 , 140:346 - 355 .N Engl J Med 2005 , 352:2609 - 2617 .", "label": "", "metadata": {}, "score": "92.80069"}
{"text": "Manuscript preparation .CF Manuscript review and preparation , critical review of the mauscript AB Manuscript preparation , Data acquisition .GB Data acquisition , Manuscript preparation - Literature search , Manuscript review .", "label": "", "metadata": {}, "score": "93.30621"}
{"text": "Yoshiyuki Suzuki Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 8470 , Japan J Gastroenterol 39:649 - 53 .", "label": "", "metadata": {}, "score": "94.315704"}
{"text": "Hiromi Yatsuji Department of Hepatology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 8470 , Japan J Hepatol 48:923 - 31 .", "label": "", "metadata": {}, "score": "95.22514"}
{"text": "Fumitaka Suzuki Research Institute for Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , Tokyo 105 8470 , Japan J Gastroenterol 37:922 - 7 .", "label": "", "metadata": {}, "score": "95.36891"}
{"text": "View Article .Pre - publication history .Copyright .\u00a9Pellicelli et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd. February 2013 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "96.45588"}
{"text": "EM Manuscript editing , Data acquisition .AP Data acquisition .MEB Manuscript review , data acquisition .CM Data acquisition .PV statistical analysis , data acquisition , manuscript editing .", "label": "", "metadata": {}, "score": "96.49418"}
{"text": "FM Data acquisition , manuscript review .CP Data acquisition , manuscript preparation , analysis of laboratory data .GB Statistical analysis , Manuscript review .", "label": "", "metadata": {}, "score": "97.68112"}
{"text": "CI , confidence interval .29 6 14 7 0 42 0 10 20 30 40 50 60 2468 1220 Week of first response Sustained responders ( % ) Fig .", "label": "", "metadata": {}, "score": "98.54616"}
{"text": "Fumitaka Suzuki Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , 105 8470 , Tokyo , Japan J Gastroenterol 39:969 - 74 .", "label": "", "metadata": {}, "score": "99.64189"}
{"text": "All the Authors declares that they do not hold or apply any patents relating to the content of the manuscript .All the Authors declares that they have not received reimbursements , fees , funding , or salary from an organization that holds or has applied for patents relating to the content of the manuscript .", "label": "", "metadata": {}, "score": "101.5741"}
{"text": "Satoshi Mamori Department of Gastroenterology , Toranomon Hospital , 2 2 2 Toranomon , Minato ku , 105 8470 Tokyo , Japan J Gastroenterol 39:776 - 82 .", "label": "", "metadata": {}, "score": "101.67172"}
{"text": "Completed .Enrollment ICMJE .Completion Date .May 2014 .Primary Completion Date .February 2013 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "104.04151"}
{"text": "All the authors declare that they do not hold or apply any patents relating to the content of the manuscript .All the authors declare that they have not received reimbursements , fees , funding , or salary from an organization that holds or has applied for patents relating to the content of the manuscript .", "label": "", "metadata": {}, "score": "104.20065"}
{"text": "Declarations .Competing interests .All the authors declares the they not have received reimbursements , fees , funding , or salary from an organization that may in any way gain or lose financially from the publication of this manuscript , either now or in the future .", "label": "", "metadata": {}, "score": "107.59354"}
{"text": "For all the Authors Adriano M Pellicelli MD Received : 15 June 2009 Accepted : 19 February 2010 Published : 19 February 2010 References 1 .", "label": "", "metadata": {}, "score": "108.48277"}
{"text": "MM Literature search , data acquisition .CD Manuscript preparation , Data acquisition , Concept .LM Manuscript review , Data acquisition .OM Laboratory analysis , Data acquisition .", "label": "", "metadata": {}, "score": "109.090355"}
{"text": "The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .Publisher conditions are provided by RoMEO .", "label": "", "metadata": {}, "score": "118.03076"}
{"text": "9 - 19 , 2011 .View at Google Scholar", "label": "", "metadata": {}, "score": "121.60223"}
{"text": "Academic Editor : Andre Castro Lyra .Copyright \u00a9 2012 Ieva Tolmane et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "135.29007"}
